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Abstract 
Prions, the infectious agents of prion diseases, are abnormal conformational variants of the 
host-encoded prion protein (PrPC) and are thought to replicate by template-directed 
conversion of native PrPC. There are multiple prion strains thought to arise from different 
conformations of PrP; of particular interest to this thesis different prion strains are differently 
able to propagate in cultured cell lines. 
This PhD focused on two main projects. Firstly, as PrPC segregates into cholesterol-rich rafts 
at the plasma membrane, the question arises whether cholesterol affects the conversion of 
PrPC to prions. Using transcriptional gene silencing we investigated whether downregulation 
of genes with a role in biosynthesis and trafficking of cholesterol affect the rate of prion 
replication. Silencing of Hmgcr and Dhcr24, two genes that encode for enzymes of 
cholesterol biosynthesis, reduced the total cholesterol levels by about 50% whilst increasing 
PrP conversion rates by two-fold, suggesting an inhibitory role of cholesterol. 
Interestingly, perturbation of cholesterol trafficking by knockdown of Npc1 and Npc2, which 
causes accumulation of cholesterol in late endosomes/lysosomes, led to diametrically 
opposing effects on prion conversion. Silencing of Npc1 in N2a cells decreased, while Npc2 
loss of function increased, conversion rates. Notably, Npc1 knockdown led to a dramatic loss 
of surface PrPC expression, a phenotype that was absent upon Npc2 silencing, suggesting that 
the Npc1-associated decrease in conversion rates is cholesterol-independent and accounted 
for by decreased PrPC, the substrate for conversion. 
A secondary project focused on identifying cellular factors underlying selective propagation 
of prion strains. We subcloned the CAD5 cell line, susceptible to both RML and 22L prion 
strains, and showed selective prion strain propagation in a small number of isolated clones. 
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Selective propagation could not be stably obtained and this project was halted in favour of 
further investigation into the role of cholesterol in prion replication.  
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1.1 Prion disease 
Transmissible Spongiform Encephalopathies (TSEs), also known as prion diseases, are 
invariably fatal neurodegenerative diseases which are known to affect (among others) 
humans, cattle and mice. Prion diseases present long disease incubation times followed by 
rapid neurodegeneration (Collinge, 2005), and are often identified post-mortem by 
characteristic deposition of misfolded prion protein in brain and other tissues including 
spleen and lymph nodes (Kimberlin and Walker, 1979, 1989, Ramasamy et al., 2003). 
Clinically prion diseases typically present with ataxia, dementia and psychiatric disorders 
such as depression (Collinge, 2001), while both human and animal disease pathology 
includes spongiform change, neuronal loss, astrocytosis, and amyloid plaque formation 
(Jeffrey et al, 1995). Prion diseases such as Creutzfeldt-Jakob disease (CJD) and Gerstmann-
Sträussler-Scheinker (GSS) can be inherited (Brown et al., 1991, Hsiao et al., 1991, Collinge 
et al., 1993) while other forms of prion diseases such as variant CJD (vCJD) can be spread by 
transfer of infectious prion protein (Hill et al., 1997, Weber and Aguzzi, 1997). Prion diseases 
were first identified in sheep and goats as Scrapie in 1732 (Plummer, 1946) and rose to 
prominence in the 1990s with the outbreak of Bovine Spongiform Encephalopathy (BSE) in 
European cattle. The BSE crisis notably demonstrated the potential for cross species 
transmission of prions with BSE, itself thought to be derived from sheep Scrapie prions (Hope 
et al, 1989), causing variant CJD (vCJD) in infected humans (Hill et al, 1997). Although the 
spread of BSE was effectively halted by mass culls of cattle the after effects of the crisis are 
still felt today, the USA for example still prohibits blood donation from people resident in the 
UK for 6 months or more between 1980 and 1996 (FDA recommendation, 1999). In recent 
history the increased incidence of chronic wasting disease (CWD) in cervids has driven a large 
part of prion disease research in North America (Robinson et al, 2012, Saunders et al, 2012, 
Davenport et al, 2015).  
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Sporadic Creutzfeldt-Jakob disease (sCJD) now accounts for the majority of human prion 
disease cases occurring at a rate of 1 person per million per year (WHO Surveillance Data). 
Recent findings suggest sub-clinical cases of vCJD in the UK may occur at a much higher rate 
of 1:2000 as a result of the outbreak of BSE in the 1990s (Gill et al., 2013). Inherited prion 
diseases have similarly rare incidences, with GSS thought to affect less than 2 in 100 million 
people per year while fatal familial insomnia (FFI) is rarer still (Ghetti et al, 1995). Both FFI 
and familial CJD include a mutation in codon 178 of PRNP which substitutes asparagine for 
aspartic acid, but can be differentiated genetically by the presence of methionine at codon 
129 in FFI patients and valine in those with familial CJD (Gambetti et al, 2003). The causative 
mutation in GSS is thought to be a proline to leucine substitution at codon 102 which has 
been found in the majority of GSS cases (Hsaio et al, 1989). The MRC Prion Unit has devoted 
considerable resources to characterising Kuru in the indigenous tribes of Papua New Guinea, 
a form of prion disease thought to be spread by ritual consumption of family members as 
part of funeral rites (Liberski et al, 2012).  
1.1.1 The Prion protein 
The Prion protein (PrP) is a 231 amino acid protein of indeterminate function encoded by 
PRNP in humans (Prnp in mice) (Oesch et al., 1985, Hornemann et al., 1997, Yusa et al., 2012) 
and incorporated into detergent resistant domains (DRMs, also known as lipid rafts) in the 
cell membrane by virtue of its C-terminal glycosylphosphatidylinositol (GPI) anchor (Stahl et 
al., 1987, Baron and Caughey, 2003). PrP contains two glycosylation sites at residues Asn 181 
and Asn 197 (human numbering) and as such can exist as un-, mono- and di-glycosylated 
forms (Ermonval et al., 2003). The prion protein is synthesised in the Endoplasmic Reticulum 
(Atkinson, 2004) and undergoes several post-translational modifications, including addition 
of N-linked oligosaccharide chains, the formation of a disulphide bond and the attachment 
to the GPI anchor (Taylor and Hooper, 2006), before the mature protein is expressed on the 
cell surface in lipid rafts. The cellular form of the prion protein is termed PrPC and is required 
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for prion replication (Oesch et al., 1985, Prusiner et al., 1987). PrPC contains three α-helices 
and a two-strand antiparallel β-sheet, whilst the disease associated isoform, PrPSc, 
incorporates a greater proportion of β-sheet in its secondary structure (Pan et al, 1993). The 
second and third helices of PrPC contain a disulphide bond between residues Cys179 and 
Cys214 (Linden et al, 2008). The folded protein contains a central hydrophobic region 
between residues 106-126 and work by Jobling and colleagues using a clone incorporating 
this region suggest the core is involved in the toxicity of PrPSc (Jobling et al, 1999). The 
unstructured N-terminus of PrP includes 5 octapeptide repeats of sequence PHGGGWGQ 
which confer metal binding ability, thus far demonstrated for copper, zinc, manganese and 
nickel (Prcina et al, 2015). A schematic of the prion protein is shown in Figure 1.1. 
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Figure 1.1 A schematic of key regions of interest in the prion protein 
The Prion protein (PrP) is a 231 amino acid protein of indeterminate function encoded by 
PRNP in humans. The N-terminal end of PrP is unstructured and contains a signal peptide 
(black) and a series of 5 octapeptide tandem repeats between residues 51 and 90 (sequence 
PHGGGWGQ, orange). In the structure region of PrP residues 106-126 form a hydrophobic 
core (purple) while the remainder of the structure includes three α-helices (green). A two-
strand anti-parallel β-sheet (blue) is formed either side of the first helix, while the second and 
third helices are linked by a disulphide bond between Cys residues 179 and 214. PrP can by 
glycosylated at residues 181 and 197 (red) and is modified to include a C-terminal GPI-anchor 
(dark blue) which incorporates the mature protein in lipid rafts. 
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Host-encoded PrPC exerts an as yet unknown physiological function in cells and indeed may 
be multi-functional (Passet et al., 2013, Onodera et al., 2014). Growing evidence suggests 
that PrP may function in cell signalling and maintenance of synaptic junctions (Re et al., 
2006). Several studies support a function of PrP in homeostasis of metals including iron 
(Singh et al., 2013), zinc (Watt et al., 2012) and copper (Zhou and Millhauser, 2012). Binding 
of copper ions causes rapid internalisation of PrPC in neuronal cells (Pauly and Harris, 1998, 
Haigh et al., 2005). It is possible that disrupted metal balance following prion infection could 
underlie toxicity in prion disease (Kawahara et al., 2011). Recently PrP has been implicated 
in Alzheimer’s disease (Nygaard and Strittmatter, 2009) and may in part contribute to 
neuronal death through excitotoxicity (Thellung et al., 2013). 
Work by several groups suggests that PrP is a ligand for the low density lipoprotein receptor-
related protein LRP1. LRP1 is known to act as a receptor for Apolipoprotein E (ApoE) (Liu et 
al., 2007) which implies a role for PrP in regulation of lipid import. LRP1 is required for 
clathrin-mediated endocytosis of PrPC (Taylor and Hooper, 2007) and functions to anchor 
PrPC to clathrin coated pits following departure from lipid rafts (Hooper et al., 2008). 
Moreover work by Roger Morris and colleagues has demonstrated that LRP1 expression is 
required for recycling of PrPC back to neuronal membranes (Parkyn et al., 2008), while work 
by Taylor and colleagues indicates LRP1 is required for copper ion-mediated endocytosis of 
PrPC (Taylor and Hooper, 2007). Further work in the Morris group has shown a requirement 
of LRP1 for internalisation of PrPSc, albeit with altered intracellular trafficking as PrPSc is 
directed towards lysosomes in place of recycling to the cell surface (Jen et al., 2010). 
1.1.2 The protein-only hypothesis 
The protein only hypothesis was first proposed by Griffith in 1967 and later refined by 
Prusiner and colleagues (Griffith, 1967, Prusiner, 1982). According to the widely accepted 
protein only hypothesis prions, the infectious agents of prion diseases, consist solely of 
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misfolded prion protein. PrPSc multiplies by catalysing the conversion of PrPC into a copy of 
the PrPSc conformer (Weissmann and Bueler, 2004). As a result of this conversion the 
predominantly alpha-helical PrPC undergoes a conformational change to PrPSc and 
incorporates a higher proportion of beta sheet into its secondary structure (Pan et al., 1993, 
Huang et al., 2013). PrPC is protease sensitive whilst PrPSc is proteinase K (PK) resistant which 
allows for experimental differentiation between PrPC and PrPSc (Borchelt et al., 1990, 
Caughey and Raymond, 1991). Due to differences in glycosylation PK-digested PrPSc displays 
distinct migration patterns when run through gel electrophoresis.  
Following the discovery that a 27-30 kDa protease resistant core of PrPSc, termed PrP27-30, 
was the infectious agent in Hamster scrapie (Oesch et al., 1985) Charles Weissmann and 
others later showed that PrPSc was encoded by a host gene named Prnp (Basler et al., 1986, 
Kretzschmar et al., 1986). Ablation of Prnp has been shown to prevent prion disease (Bueler 
et al., 1993) however the expression of Prnp is not sufficient to cause prion disease without 
the introduction of PrPSc unless the expressed gene contains mutations associated with 
spontaneous prion generation (Hsiao et al., 1990). Expression of hamster Prnp in Prnp-
knockout mice, which are resistant to infection with mouse prions, has been shown to be 
sufficient for propagation of hamster prions following inoculation with infected hamster 
brain homogenate (Bueler et al., 1993). Furthermore, depletion of PrPC in mice following 
prion infection reduces both toxicity and spread of prion disease (G et al., 2003).  
More recent investigations using cell free conversion assays suggest prion replication is 
promoted by cofactors such as polyanions (Deleault et al, 2003) and lipids (Baron and 
Caughey, 2003, Deleault et al 2005). Although not a requirement for prion conversion (Baron 
and Caughey, 2003, Lewis et al., 2006, Raymond et al., 2012) the GPI anchor is found in both 
PrPC and PrPSc and is sensitive to cleavage by phosphatidylinositol specific phospholipase C 
(PIPLC) (Stahl et al., 1987). It is possible that GPI-anchoring increases the proximity of PrPC 
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and PrPSc in lipid rafts, an idea discussed in greater detail in section 1.2.2 below. Notably, 
although recombinant prions formed in the absence of mammalian cofactors remained 
infectious, inclusion of RNA and lipids in cell free conversion assays greatly increased the 
infectivity of prions produced (Deleault et al, 2007, Wang et al, 2010). It is possible that 
detergents used to extract prion seeds could form an interface similar to lipid rafts in 
cofactor-free assays, and remarkably recombinant prion fibrils produced using detergent-
free methods are insufficient to cause disease in animals (Ma, 2012). 
1.1.3 Prion strains 
Whilst all prions are infectious they can be divided into strains which can be characterised 
by distinct disease incubation times and pattern of brain lesions and deposition of abnormal 
PrP (Fraser and Dickinson, 1973, Bruce, 1993). Prion strains can be further characterised by 
differences in the migration of the protease-resistant protein on Western blots which varies 
according to the degree of glycosylation of the strain (Collinge et al., 1996). Prion strains can 
be stably passaged in vivo (Bruce, 1993) which has allowed for relatively high scale 
production of mouse brain homogenates infected with prion strains such as RML. Differences 
between prion strains do not appear to be due to differences in amino acid sequence as 
multiple strains can be propagated on the same form of PrPC (Hope et al., 1986, Collinge and 
Clarke, 2007). Differences between strains may be determined by the conformation of PrPSc, 
and studies in [PS1+] yeast prions have demonstrated different strain properties of different 
conformers (Tanaka et al., 2006). Prions strains have been suggested to be quasispecies of 
different conformational variants of PrP (Collinge, 2010), and it is thought that a dominant 
subspecies within each strain may give rise to the characteristic differences between prion 
strains (Peretz et al., 2001). Prion strains have shown changes in strain characteristics when 
propagated in different cell and tissue types (Li et al., 2010) which may follow adaptation as 
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a recessive conformer outcompetes the dominant conformer in a new environment (Mahal 
et al., 2010). These adaptations are discussed in greater detail below. 
1.1.2 (a) The species barrier 
Differences in the primary structure of PrP between different species are thought to 
contribute to a ‘species barrier’ which limits transmission of prions between species. It is 
likely that differences in conformation of PrP between species also contribute to the species 
barrier. Zoonotic transmission of prion disease still occurs as seen in the spread of vCJD from 
BSE-infected beef in 1990s Britain (Hill et al., 1997) and it is possible for prion strains to 
overcome the species barrier experimentally (Nakamura et al., 2000, Shi et al., 2012). Given 
the Quasispecies hypothesis, which states that prion strains contain a pool of PrPSc 
conformers, it is possible that breaches in the species barrier are due to conformers which 
are replication-competent with similar PrP primary structures (Hagiwara et al., 2013). This 
theory predicts that different prion strains may spread more readily across species due to 
the presence of different PrPSc conformers. 
1.1.2 (b) Selective propagation of prion strains in vitro 
There is a marked discrepancy between susceptibility to different prion strains in in vivo and 
in vitro models. Whilst many prion strains of a given species can be propagated in rodents, 
like mice or bank voles (Bruce, 1993, Watts et al., 2014), cultured cells often propagate prion 
strains selectively (Mahal et al., 2007, Li et al., 2010). Previous work in our group has shown 
that some cell lines are heterogeneous with regard to strain selectivity and prion replication, 
with subcloning of N2a cells yielding both highly susceptible and prion resistant subclones 
(Klohn et al., 2003). We have recently reported that genes involved in extracellular matrix 
(ECM) remodelling regulate susceptibility to prion replication (Marbiah et al., 2014) in these 
cells and it is possible that cellular factors may also underlie susceptibility to different prion 
strains.  
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Some cell lines propagate prion strains promiscuously, although at different rates (Mahal et 
al., 2007). Interestingly, the work of Mahal and colleagues also demonstrated that prion 
strains which are readily propagated in one cell line may not be replicated in a different cell 
line, irrespective of   its general susceptibility to other prion strains. This suggests that cellular 
factors not only determine the susceptibility to prion infection, but also to prion strains. One 
potential explanation for this in light of the quasispecies theory of prion strains is that 
different cellular factors alter or interact with conformational variants of PrPC, which could 
limit their ability to replicate. 
1.1.2 (c) Darwinian strain selection 
An elegant study by Charles Weissmann and colleagues (Li et al., 2010) provided 
experimental evidence for adaptations within a prion strain passaged in both mouse brain 
and immortalised cells. A ‘cell-adapted’ form of the initial prion strain outcompeted its 
‘brain-adapted’ counterpart when tested in cultured cells, whilst the opposite was true when 
the same strains were used to infect mouse brain. Remarkably, by applying selection 
pressure by incubating cells with the glycosylation inhibitor swainsonine in a separate 
experiment, the researchers were able to isolate a resistant sub-strain which altered the 
characteristics of the prion strain. Swainsonine-resistant prions were outcompeted by 
swainsonine-susceptible species in the absence of the drug, which suggests prion strains are 
capable of adapting to environmental pressure. Working in the Weissmann lab Mahal et al 
(2010) contributed to this work, showing that isolated clones of prion-infected R33 cells 
yielded prion strains with altered characteristics. In the same study the authors also 
demonstrated that differentially adapted prion strains exhibited different conformational 
stabilities of PK-resistant PrP similar to the work of Peretz et al (2001), who showed that 
different prion strains were differentially susceptible to denaturation by guanidine. These 
experiments lend evidence to the theory that prion strains exist as quasispecies, containing 
a mix of various PrP conformers of which one or more are dominant and confer the strain 
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characteristics (Collinge, 2010). In response to environmental pressure it is possible that a 
non-dominant conformer is able to replicate faster and out-compete the dominant 
conformer thus changing the strain characteristics. There is also evidence for competition 
between stable prion strains. Work by Kimberlin and Walker has demonstrated that the 22A 
prion strain blocks infection of the 22C strain (Kimberlin and Walker, 1985). This effect was 
prevented by denaturing 22A with urea, suggesting that an infectious blocking strain is 
required to limit propagation of a second prion strain. It is possible that established infection 
with 22A prions, which were inoculated into mice 105 days prior to 22C, converted PrPC more 
efficiently that 22C and so depleted potential substrate for 22C propagation. A hypothetical 
example of quasispecies selection and prion strain selection is shown in Figure 1.2 
(reproduced from Collinge, 2010). 
Although the species barrier which prevents zoonotic transmission of prions is largely 
thought to be due to differences in the primary structure of PrP between species (Vanik et 
al., 2004, Kurt et al., 2015) strain adaptation, and by extension selection of prion 
quasispecies, may help to explain why species barriers are occasionally breached. In 
particular some PrPSc conformations may be more readily able to convert on a variety of host 
species than other strains due to a favourable conformation for replication (Torres et al., 
2014). Prion strains which have been adapted to other species show increased infectivity 
following multiple passages (Plinston et al., 2011) suggesting that the prion strain adapts to 
propagate more efficiently in a new host species.  
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Figure 1.2 Prion strain selection and mutation due to environmental pressure (reproduced 
from Collinge, 2010) 
A A prion strain may contain multiple PrPSc conformers. A given prion strain may be readily 
transmitted between host species which express similar conformations of PrPC such as species 
I and II. Transmission barriers may arise when there is no overlap between PrP conformations 
such as with species I and III. B Host factors maintain selection pressure on prion strains. 
Transmission within a species expressing the same PrPC conformers maintains strain 
characteristics (a) whilst the availability of different PrP conformations in the same or 
different species may alter strain characteristics (b, c). Barriers to transmission arise between 
different species which express different PrP conformers (d) although these can be overcome 
with mutation.  
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1.1.4 PrPSc as a marker of infectivity 
 PrPSc has been widely accepted as a biomarker of prion infection (Oesch et al., 1985, Caughey 
and Raymond, 1991) but there is uncertainty regarding prion toxicity with some suggesting 
that an unknown toxic species causes neuronal death in prion disease (Ashe and Aguzzi, 
2013). Some infectious prions remain sensitive to PK (Tzaban et al., 2002) which may be due 
to altered stability of different PrP conformers in prion strains. Ongoing work in the MRC 
Prion Unit indicates that prions themselves are not the toxic species but instead induce the 
formation of toxic species (Sandberg et al., 2011). 
In this thesis PK-resistant PrPSc is used as a measure of prion propagation. This definition 
follows the biochemical definition of the infectious agent of prion disease outlined by the 
Protein-Only hypothesis (Oesch et al., 1985). This definition is key to our chosen means of 
determining prion propagation in cells: the Scrapie Cell Assay (SCA). The endpoint of the SCA 
is the Elispot assay which determines the number of PrPSc-positive cells in a given sample by 
PK-digestion of PVDF membrane-bound cells followed by detection of PK-resistant PrP by 
immunohistochemistry (Klohn et al., 2003). 
1.1.5 PrPC trafficking  
The prion protein is not wholly resident in the plasma membrane, and it has been suggested 
that prion conversion occurs during intracellular trafficking of PrPC. Both PrPC and PrPSc leave 
lipid rafts prior to internalisation, however the mechanism of internalisation remains 
unclear. Internalisation of PrP through caveolae has been shown in Chinese hamster ovary 
cells (Vey et al., 1996; Peters et al., 2003), whereas immunogold detection suggests 
internalisation through clathrin-coated pits in neuronal cells (Shyng et al., 1994; Shyng et al., 
1995; Sunyach et al., 2003). When trafficked internally PrP is initially present in early 
endosomes, before being sorted for recycling in the endosomal recycling compartment (ERC) 
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or redirected to lysosomes for degradation (Maxfield and Mcgraw, 2004, Jen et al., 2010). 
PrPC trafficked in endosomes is recycled to lipid rafts in the plasma membrane (Morris et al., 
2006). Work by Chiara Zurzolo and colleagues suggests cholesterol may partially determine 
the degree to which PrP is recycled – in normal function the majority of PrP was recycled to 
the cholesterol-rich ERC, however treatment with 4- hydroxytamoxifen to induce cholesterol 
accumulation in late endosomes increased trafficking of PrPSc to lysosomes (Browman and 
Zurzolo, 2013). Kinetic studies indicate fairly rapid turnover of PrPC with a half-life of less 
than 5 hours in neuronal cell membranes (Caughey et al., 1989, Borchelt et al., 1990). 
Recycling of PrPC from lipid rafts and through endosomes is summarised in Figure 1.3. There 
is some evidence that the endosomal/lysosomal compartment is the site of conversion of 
PrPC to PrPSc (Borchelt et al., 1992, Marijanovic et al., 2009, Yim et al., 2015). Multiple cell-
free assays demonstrate that acidic environments are required for formation of PrPSc 
(Kocisko et al., 1995, Alonso et al., 2001, Qi et al., 2012). Notably a recent study suggests that 
the low pH in lysosomes facilitates fibrilisation of misfolded PrP (Qi et al., 2012). In 1992 
Laszlo et al showed accumulation of high levels of PrPSc in lysosomes and suggested that this 
represented rapid conversion of PK-resistant PrP in these organelles (Laszlo et al., 1992). A 
clear rebuttal to this theory is of course that lysosomes act to degrade incorrectly folded 
proteins (Liu et al., 2012) and PrPSc is known to be trafficked to lysosomes in prion-infected 
cells (Goold et al., 2013). As such the accumulation seen by Laszlo et al may be the result of 
increased trafficking of PrP to the lysosome in a cellular attempt to clear PrPSc. 
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Figure 1.3 PrPC leaves lipid rafts for intracellular trafficking (Adapted from Linden et al, 
2008 and Browman and Zurzolo, 2013) 
PrPC (red) resides in lipid rafts (green) in the plasma membrane. Prior to internalisation PrP 
leaves lipid rafts and is endocytosed through either clathrin-coated pits or caveolae being 
trafficked through the endosomal (blue) system. In normal function the majority of PrP is 
recycled back to the plasma membrane with a small amount targeted for degradation in 
lysosomes (yellow). If cholesterol is redirected from the endosomal recycling compartment 
(green) towards late endosomes (not shown) PrPSc trafficking has been shown to redirect to 
lysosomes (Browman and Zurzolo, 2013). 
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1.2 Lipid rafts 
The cell plasma membrane is continuous and incorporates a mosaic of lipid and protein 
structures which support various cellular functions. Lipid rafts, also known as detergent 
resistant membrane domains (DRMs), are lipid-rich regions of the cell membrane which 
display a more ordered structure than the surrounding membrane (Simons and Ikonen, 
1997) and facilitate attachment and internalisation of GPI anchored membrane proteins such 
as PrP (Brown and Rose, 1992). Lipid rafts typically include 3-5-fold greater cholesterol than 
surrounding plasma membrane, which acts as an interstitial ‘glue’ between other lipids 
(Korade and Kenworthy, 2008). The amphipathic nature of cholesterol and sphingomyelin 
means they are able to pack closely together in rafts and imbed their hydrophobic tails within 
the plasma membrane (Fantini et al, 2004).  Cholesterol interacts preferentially with 
sphingolipids in rafts, and due to the rigid nature of its sterol group partitions to the more 
rigid, more saturated acyl chains of sphingolipids where its conical shape allows it to pack 
tightly into gaps between sphingolipids (Rietveld and Simons, 1998). Acyl chains are thought 
to be straighter and more saturated in clustered rafts, forming a so-called ‘lipid ordered 
state’ (Lingwood and Simons, 2007). Lipid rafts demonstrate resistance to non-ionic 
detergents at low temperatures, an effect thought to be mediated by cholesterol (Naslavsky 
et al, 1997). It is likely that the tight packing of lipids in rafts mean hydrophobic regions are 
less accessible to detergents, and so resist a low level of detergent which solubilises the 
surrounding plasma membrane allowing for raft extraction (Brown and London, 1998). 
Lipid rafts can be further divided into planar rafts, which are continuous with the plasma 
membrane and incorporate flotillin proteins, and caveolae which are widely expressed in the 
nervous system and cause detectable deformation of the plasma membrane (Allen et al, 
2007). It has been speculated that the different properties of planar rafts and caveolae 
segregate signalling molecules and play an important role in neurotransmission (Masserini 
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et al, 1999, Owen et al, 2012). PrP is enriched in cholesterol-sphingolipid lipid rafts which 
have previously been suggested to both facilitate and inhibit prion replication by various 
researchers. 
1.2.1 Controversy of lipid rafts 
Although becoming more widely accepted the very existence of lipid rafts remains debatable 
(Hawkes and Mak, 2006). Lipid rafts remain difficult to visualise by conventional microscopy 
(Owen et al., 2012) and have required indirect methods of observation to investigate 
(Jacobson et al., 2007). These difficulties have led some to suggest that rafts may be an 
artefact of detergents used in their extraction (Chamberlain, 2004). More recent studies 
provide continuing evidence for the existence of lipid rafts including detection by atomic 
force microscopy (Lawrence et al., 2003), super-resolution microscopy (Owen et al., 2012), 
and the replication of lipid-ordered domains across model cell membranes (Dietrich et al., 
2001). Growing evidence suggests that lipid rafts are formed in the Golgi following 
sphingolipid synthesis and are then trafficked to cell membranes (Simons and Van Meer, 
1988). Regardless of this debate growing evidence suggests multiple roles for ordered lipid-
rich domains in membranes in cellular functions (Chu et al., 2004, Zhu et al., 2006). Proteins 
including PrP have consistently been found in lipid-rich fractions of the cell membrane 
(Crameri et al., 2006, Taylor et al., 2009) with some studies suggesting lipids such as 
cholesterol are required for cell surface presentation of PrPC (Gilch et al., 2005). Lipid rafts 
are implicated in the entry of several viruses into cells (Ikeda et al., 2006, Zhu et al., 2012) 
and may act as a site of conversion of PrPC to PrPSc.  
1.2.2 Association of GPI-anchored proteins with lipid rafts 
PrP and other membrane proteins such as Thy1 incorporate into lipid rafts by virtue of their 
GPI-anchors (Stahl et al., 1987, Paulick and Bertozzi, 2008). Incorporation into lipid rafts is a 
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requirement for cell surface expression of PrP (Gilch et al., 2005, Caputo et al., 2009) and 
some have suggested that lipid rafts are a potential site for prion propagation (Fantini et al., 
2002, Cui et al., 2014). In this model rafts act as substrates by increasing the proximity of 
PrPC and PrPSc and thereby increasing the likelihood of prion conversion. In contrast, lipid raft 
association has been shown to stabilise PrPC (Sarnataro et al., 2004) which may impair 
misfolding. The GPI anchor is added to PrPC post-translationally (Stahl et al., 1987) and 
anchoring of PrPC into lipid rafts is likely to be important for the function of mature PrPC 
(Lewis and Hooper, 2011). Some evidence suggests that PrPC is incorporated into rafts early 
in the secretory pathway (Naslavsky et al., 1997, Sarnataro et al., 2004), indicating that lipid 
raft association is required for correct trafficking of PrP. 
In 2005, Sabine Gilch and colleagues reported that cholesterol is required for cell surface 
presentation of PrP (Gilch et al., 2005), putatively as a result of GPI-directed incorporation of 
PrP into cholesterol-rich lipid rafts which cannot form in the absence of cholesterol. Both 
PrPC and PrPSc reside in lipid rafts (Vey et al., 1996, Naslavsky et al., 1997), fuelling early 
suggestions that rafts are the site of prion conversion. Despite these findings the site(s) of 
prion replication remain unknown, and more recent evidence indicates that conversion may 
occur once PrPC leaves lipid rafts (Marijanovic et al., 2009, Yim et al., 2015). Lipid rafts are 
also involved in intracellular trafficking of PrP (Vey et al., 1996) and have been shown to 
facilitate PrP internalisation via caveolae (Peters et al., 2003, Sarnataro et al., 2009). Multiple 
sources suggest that PrP is endocytosed via clathrin coated-pits (Shyng et al., 1995, Sunyach 
et al., 2003, Taylor and Hooper, 2007) although a clathrin-independent pathway has also 
been shown (Kang et al., 2009). Evidence suggests that PrPC leaves rafts for clathrin-mediated 
internalisation (Sunyach et al., 2003) and is recycled back to the plasma membrane via early 
endosomes (Magalhaes et al., 2002). It appears likely that PrPC is internalised through 
multiple pathways even in the same cell (Lewis and Hooper, 2011) and there is evidence that 
PrP can also be taken up directly via caveolae (Taylor and Hooper, 2006). Whilst lipid raft 
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disruption and inhibition of clathrin-mediated endocytosis both reduce uptake of PrP, it was 
recently shown that PrP internalisation is only completely abolished by inhibiting both 
pathways (Sarnataro et al., 2009).   
1.2.3 The composition of PrP-containing lipid rafts 
Seminal work by Naslavsky and colleagues demonstrated that cholesterol and sphingolipids 
form the principal components of lipid rafts containing PrP (Naslavsky et al., 1997). 
Cholesterol in particular has been shown to be required for cell-surface expression of PrP 
(Gilch et al., 2005). The ganglioside GM1 is a sphingolipid component of lipid rafts which can 
be isolated in PrP-containing fractions of cell lysates run on sucrose gradients (Naslavsky et 
al., 1997, Crameri et al., 2006, Annaba et al., 2008). A sphingolipid binding domain similar to 
the V3 loop of HIV envelope protein has been identified in PrP (Mahfoud et al., 2002). 
Interestingly this domain includes the site of the E200K mutation which is associated with 
familial CJD (Prusiner, 1998); suggesting sphingolipid binding may be involved in prion 
formation. Aside from sphingolipids and cholesterol lipid rafts can contain multiple proteins 
which require rafts for cell surface localisation (Loertscher and Lavery, 2002, Suzuki et al., 
2007). A recent review by Nigel Hooper (2011) explored the association between PrP-
containing lipid rafts and the heparin sulphate proteoglycan (HSPG) glypican-1. Glypican-1 
may facilitate association of PrPC with lipid rafts and depletion of glypican-1 impaired prion 
replication (Taylor et al., 2009). 
1.3 Suggested roles of lipids in prion conversion 
The role of lipids in prion replication is unclear and controversially discussed in the literature. 
Cell-free models such as Protein Misfolding Cyclic Amplification (PMCA) suggest certain lipids 
may be required as co-factors for prion replication (Wang et al., 2010). The close association 
of PrP with lipid rafts would suggest that these lipids act as the required co-factors. However 
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in direct contrast to this, cell-based models, which provide a full complement of regulatory 
genes for lipid metabolism, suggest PrP is stabilised in lipid rafts (Sarnataro et al., 2004) which 
would be expected to inhibit prion replication.  
1.3.1 Lipids as co-factors for prion propagation 
Early evidence for the requirement of lipids in prion replication comes from Stanley 
Prusiner’s lab where it was demonstrated that the cholesterol synthesis inhibitor lovastatin 
decreased PrPSc in infected cells (Taraboulos et al., 1995), putatively by disrupting the 
association between PrP and lipid rafts. Indeed more recently statin treatment has been 
shown to prolong lifespan in prion-infected mice (Mok et al., 2006, Kempster et al., 2007, 
Haviv et al., 2008). However, these studies also indicate that increased lifespan may be a 
pleiotropic effect of statins as neither levels of cholesterol or PrPSc were found to be reduced 
by statin treatment. Studies in whole-cell and artificial membrane models complicate this 
picture, suggesting that lipid rafts stabilise PrPC and so may limit prion replication (Eberl et 
al., 2004, Sarnataro et al., 2004, Hicks et al., 2006).  
Protein Misfolding Cyclic Amplification (PMCA), first developed by Gabriela Sarborio in 
Claudio Soto’s group (Saborio et al., 2001), is a key cell-free assay in the study of prion 
disease. PMCA reproducibly produces PK resistant PrP forms, albeit with low infectious titres 
(Timmes et al., 2013), through multiple rounds of incubation and sonication of a PrPSc ‘seed’ 
in presence of excess PrPC. In the incubation phase PrPC is incorporated into oligomers 
following template conversion to PrPSc, whilst the sonication phase is thought to disrupt 
oligomeric structures producing further PrPSc seeds for subsequent rounds of incubation 
(Saborio et al., 2001). More recent developments in PMCA have revealed the minimal 
requirements for PrPSc amplification include lipids which can be synthetic such as POPG (1-
palmitoyl-2-oleoylphosphatidylglycerol) (Wang et al., 2010). In many PMCA experiments 
seeds are derived from infected brain homogenate and purified for seeding into recombinant 
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PrPC (Panza et al., 2010, Luers et al., 2013), essentially by removing all lipid components from 
the system. Work in the lab of Surachi Supattapone shows that phosphatidylethanolamine 
(PE) is often co-purified with seeds and acts as a co-factor for prion replication, with synthetic 
PE being sufficient for formation of PrPSc from recombinant PrP in PMCA (Deleault et al., 
2012). In light of early findings that cell-free prion replication required insertion of PrPSc into 
model membranes (Baron et al., 2002) some have suggested that lipids provide a substrate 
to increase the proximity of PrPC and PrPSc and so aids conversion (Fantini et al., 2002). Due 
to differences between cell-free and cell-based models, it is possible that whilst lipids may 
be required for prion replication in PMCA and other cell-free models this may not be the case 
in host cells. 
1.3.2 Lipids as inhibitors of prion propagation 
Chiara Zurzolo and colleagues have demonstrated that association with cholesterol-rich rafts 
stabilises immature PrPC (Sarnataro et al., 2004). This work showed that immature PrPC 
initially associates with cholesterol-rich rafts in the endoplasmic reticulum, and that 
cholesterol depletion slows PrP maturation and can lead to misfolding. Interestingly, these 
effects could not be replicated by depleting sphingolipids, indicating cholesterol is sufficient 
to stabilise PrPC in lipid rafts. It stands to reason that if cholesterol stabilises immature PrPC 
against misfolding, it may also protect against template-induced conversion into PrPSc. In a 
cell-free model of prion conversion Baron and Caughey demonstrated that PrPC linked to 
cholesterol and sphingolipid rich raft-like liposomes by a GPI anchor resisted conversion into 
PrPSc (Baron and Caughey, 2003). Interestingly, this resistance was overcome by treating 
samples with PIPLC to cleave the GPI anchor, suggesting that binding to lipid rafts prevented 
the use of PrPC as a substrate for prion conversion. 
It is likely that lipids other than cholesterol influence prion propagation. Indeed 
oligodendrocytes, which contain high levels of sphingolipids, are resistant to prion infection 
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(Prinz et al., 2004) whilst both neurons and astrocytes are susceptible. In 1999 Naslavsky and 
colleagues demonstrated that the rate of prion replication is inversely proportional to the 
sphingomyelin content of cultured prion-infected neuroblastoma cells (Naslavsky et al., 
1999). Treatment of cells with fumosin B1, which inhibits ceramide synthase and thus the 
production of several sphingolipids, decreased both sphingomyelin and GM1 whilst 
increasing levels of PrPSc. Further study in the same report showed that treatment with 
sphingomyelinase to selectively deplete sphingomyelin produced a similar increase in PrPSc 
without altering GM1 level. In these experiments there was little or no change observed in 
PrPC production or turnover. The authors noted that this result was in direct contrast to the 
work of Albert Taraboulos and colleagues which demonstrated reduced PrPSc in cells 
following inhibition of cholesterol synthesis using lovastatin (Taraboulos et al., 1995). 
1.3.3 The role of cholesterol in neurodegenerative diseases 
Perturbations in cholesterol metabolism have been shown to affect neurodegenerative 
diseases other than prion disease. Cholesterol may be neuroprotective in Alzheimer’s 
disease (Crameri et al., 2006) whilst impaired cholesterol trafficking gives rise to progressive 
neurodegeneration in Niemann-Pick type C (NPC) disease (Sturley et al., 2004). The major 
genetic risk factor currently known for Alzheimer’s disease is the ε4 allele of the gene 
encoding Apolipoprotein E (ApoE) (Corder et al., 1993, Strittmatter et al., 1993, Liu et al., 
2015). ApoE transports cholesterol between cells and is discussed along with key players in 
cholesterol metabolism in greater detail below (section 1.4). Other cholesterol-related genes 
have been implicated in Alzheimer’s disease, possibly as a result of altered membrane lipid 
composition altering cleavage of APP (Malnar et al., 2012, Maulik et al., 2013). Some research 
suggests that treatment with statins, which lower cholesterol, may protect against 
neurodegeneration (Fassbender et al., 2001, Haag et al., 2009) however there is evidence 
that this may be a result of reduction in co-morbid hypercholesterolemia-induced non-
Alzheimer’s vascular dementia (Kalback et al., 2004, Wollmer, 2010). Conversely expression 
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of DHCR24, which encodes a key enzyme for cholesterol synthesis, has been found to 
correlate with protection against Alzheimer’s disease and indeed limits disease-associated 
processing of APP (Crameri et al., 2006).  
Impaired cholesterol trafficking through lysosomes underlies neurodegeneration in NPC 
disease. Cholesterol efflux from lysosomes is mediated by Npc1 and Npc2 and loss of 
function of either gene leads to a characteristic accumulation of cholesterol in lysosomes 
(Sturley et al., 2004). Similarly ablation of Npc1 has been shown to cause accumulation of 
GM1 in lysosomes (Sugimoto et al., 2001) which may indicate disrupted recycling of lipid 
rafts. Npc1 is a large transmembrane protein which accepts cholesterol from Npc2, a small 
soluble protein in the lysosomal lumen (Carstea et al., 1997, Naureckiene et al., 2000). The 
vast majority of Niemann-Pick type C cases are caused by loss of Npc1 function, with Npc2 
deficiency accounting for approximately 5% of all cases (Vance, 2006). Defective trafficking 
by Npc1 and Npc2 is associated with several other phenotypes alongside lysosomal 
cholesterol accumulation, including impaired autophagy (Sarkar et al., 2013) and altered 
processing and localisation of APP (Runz et al., 2002, Kosicek et al., 2010, Malnar et al., 2012). 
In 2006 Npc1-deficiency was shown to impair processing of glypican-1 leading to production 
of reactive oxygen species (Mani et al., 2006). Altered processing of glypican-1 following loss 
of Npc1 function may further contribute to lipid raft disruption alongside cholesterol 
accumulation. 
1.4 Cholesterol metabolism 
As the principal component of PrP-associated lipid rafts cholesterol is a prime target for 
examining the role of cholesterol in prion replication. Cholesterol metabolism is involved in 
numerous diseases including atherosclerosis (Libby et al., 2011) and Alzheimer’s disease 
(Refolo et al., 2000) and as such is widely studied. We were able to translate the many tools 
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already in use in cholesterol research to modulate intracellular cholesterol in our models of 
prion replication. 
1.4.1 Cholesterol Synthesis 
Cholesterol synthesis is complex and tightly regulated, presenting opportunities as well as 
challenges for drug and gene induced changes to cellular cholesterol levels. There is a distinct 
separation between brain and peripheral cholesterol as lipoprotein molecules which 
transport cholesterol between cells do not easily cross the blood-brain barrier (Dietschy, 
2009). The brain accounts for approximately 25% of total body cholesterol which is nearly 
entirely synthesised locally (Pfrieger, 2003).  In the central nervous system (CNS) the majority 
of cholesterol is synthesised in glia and is exported to lipoproteins at the cell membrane 
allowing for extracellular trafficking of lipoprotein-bound cholesterol to neurons (Hayashi, 
2011). The vast majority of cholesterol in the CNS is in the form of unesterified free 
cholesterol, a key component of neuronal and astrocyte membranes (Pfrieger and Ungerer, 
2011) as well as myelin sheaths of oligodendrocytes (Saher et al., 2005). During development 
CNS cholesterol is produced rapidly, with the rate of production declining in adult brains as 
an efficient recycling system maintains cholesterol homeostasis (Dietschy, 2009). Following 
synthesis cholesterol is transported to cell membranes via the Golgi and Trans-Golgi complex 
(Simons and Ikonen, 2000), where it incorporates into both raft and non-raft domains 
(Ikonen, 2008). 
Cholesterol is synthesised in the Endoplasmic Reticulum (ER) from acetyl-CoA (Goldstein and 
Brown, 1990). The mevalonate pathway, which produces cholesterol, is highly complex 
(Yeganeh et al., 2014) and produces many physiologically required metabolites including 
ubiquinones (Bentinger et al., 2010) and prenylated proteins (Sinensky and Lutz, 1992). 
Isoprenoids, produced from a non-cholesterogenic branch of the mevalonate pathway 
(Chang et al., 2013), are known to be affected by prion propagation (Guan et al., 1996). 
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Nordström et al demonstrated that treatment with forskolin, an isoprenoid derivative, 
increased the levels of PrPSc in prion-infected GT1-1 cells (Nordstrom et al., 2009). Thus 
disrupting the mevalonate pathway has the potential to perturb prion replication and so care 
is required to ensure observed effects can be attributed to cholesterol. A non-exhaustive 
version of the mevalonate pathway which highlights key genes targeted in this study is shown 
in Figure 1.4.  Cholesterol synthesis is tightly regulated by transcriptional feedback to the 
rate-limiting enzyme 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) encoded by the 
Hmgcr gene. Statins, a classical family of cholesterol-lowering drugs inhibit HMGCR activity 
(Farmer, 1998) and have been shown to reduce the PrPSc load in prion infected neuronal 
cells. Ina Vorberg and colleagues have shown that chronic prion propagation in cells gives 
rise to increased expression of cholesterogenic genes, including the sterol regulatory 
element binding protein (Srebp2) (Bach et al., 2009) which suggests that prions may disrupt 
the cholesterol metabolism. Downstream of HMGCR, the mevalonate pathway branches 
after the production of farnesyl diphosphate to form several non-sterol molecules 
(Nurenberg and Volmer, 2012). Past research has supplemented cells with mevalonate 
following HMGCR inhibition to provide for these non-steroidal pathways (Taraboulos et al., 
1995). However as mevalonate is produced directly from acetoacetyl CoA by HMGCR 
(Goldstein and Brown, 1990) the net change in cholesterol caused by these treatments 
remains unclear.  
During the final stages the cholesterol synthesis pathway branches with the final enzymes 
acting in an indeterminate sequence (Zerenturk et al., 2013). Cholesterol synthesis 
culminates with the action of 3β-hydroxysteroid-Δ24 reductase which is encoded by Dhcr24 
and catalyses the conversion of desmosterol to cholesterol by reduction of the ∆24 double 
bond (Waterham et al., 2001). Silencing Dhcr24 has been shown to cause desmosterolosis, a 
severe developmental disorder characterised by increased plasma desmosterol (Waterham 
et al., 2001, Zerenturk et al., 2013). Although principally involved in cholesterol synthesis, 
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Dhcr24 has also been shown to have a neuroprotective role in ER stress (Lu et al., 2014) and 
is known to regulate Ras-induced senescence (Wu et al., 2004). Dhcr24 was originally 
described as a neuroprotective factor in Alzheimer’s disease, Seladin-1, and was found to be 
downregulated in brain areas susceptible to Alzheimer’s disease (Greeve et al., 2000, Peri 
and Serio, 2008).  It is possible given the nature of protein aggregation in both Alzheimer’s 
and prion diseases that perturbed cholesterol synthesis could affect these diseases in similar 
ways. Dhcr24 expression increases dose-dependently after incubation with simvastatin 
(Ramos et al., 2012) which may indicate an adaptive response to impaired cholesterol 
synthesis. Dhcr24 activity can be inhibited by triparanol (Spann et al., 2012) which shows 
some non-specific activity and also inhibits Hedgehog pathway signalling (Bi et al., 2012). 
Gene silencing of Dhcr24 with multiple effective siRNAs provides a relatively clean method 
of reducing cholesterol in cells by excluding the possibility of off-target effects. 
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Figure 1.4 Cholesterol is synthesised in the Mevalonate Pathway 
Cholesterol is synthesised from Acetyl CoA by a tightly regulated multistep pathway. Dashed 
arrows indicate multiple steps not shown here. HMG-CoA: 3-hydroxy-3 -methylglutaryl CoA, 
HMGCR: 3-hydroxy-3-methylglutaryl CoA reductase, DHCR24: 3β-hydroxysteroid-Δ24 
reductase. Black text denotes a metabolite and blue an enzyme. Branched pathway at 
DHCR24 denotes multiple steps which occur in indeterminate order (parallel Bloch and 
Kandutsch-Russell pathways) but culminate with action of DHCR24. Adapted from (Goldstein 
and Brown, 1990, Zerenturk et al., 2013, Yeganeh et al., 2014) 
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1.4.2 Cholesterol Import 
Cholesterol in neurons is predominantly imported via a lipoprotein-based shuttle system 
(Hayashi, 2011, Pfrieger and Ungerer, 2011). An attractive method of cholesterol depletion 
in cultured cells is to use lipoprotein-deficient serum in place of Foetal Bovine Serum (Narita 
et al., 1997, Hawes et al., 2010). Notably reduced fat serum (an early form of lipoprotein-
deficient serum) was required to show effects of HMGCR inhibition on PrPSc levels in the work 
of Tarabolous et al (1995). Given the reliance of neurones in the CNS on glial cells for 
cholesterol lipoprotein-deficient serum may have serious adverse effects in cell culture but 
remains a common method for cholesterol depletion in vitro. The half-life of free cholesterol 
in the periphery is fairly short compared to cholesterol in the CNS (Andersson et al., 1990) 
and in most cases cholesterol will instead be associated with lipoproteins for transport 
between cells (Hayashi, 2011).  
The ε4 allele of ApoE is widely accepted as the major genetic risk factor for Alzheimer’s 
disease (Corder et al., 1993, Strittmatter et al., 1993, Liu et al., 2015). ApoE acts as a shuttle 
and transports cholesterol between cell membranes, typically acting in the brain to deliver 
cholesterol from glia to neurones (Rapp et al., 2006). The activity of ApoE is particularly 
important in the brain as other key apolipoproteins are almost entirely absent (Poirier et al., 
1995). ApoE4 differs from the ‘wild type’ ApoE3 allele only by a single cysteine to arginine 
amino acid change at position 112 (Hauser and Ryan, 2013), but binds cholesterol with much 
greater affinity (Li et al., 2013). Whilst no direct causative link has been described for ApoE4 
in prion diseases a genome wide association study (GWAS) performed by Calero et al (2011) 
indicated that sCJD patients exhibited a higher occurrence of ApoE4 than a control 
population, suggesting that perturbed cholesterol trafficking is a risk for prion disease. 
Cholesterol and other lipoprotein components are imported into cells via low-density 
lipoprotein receptor-related proteins (LRPs) in the cell membrane (Zerbinatti and Bu, 2005). 
The principal receptors for ApoE are LRP1 and LRP8 (Jaeger and Pietrzik, 2008), although 
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several other LRPs have been identified with similar functions (May et al., 2007). Growing 
evidence suggests that LRPs are involved in signal transduction (Bao et al., 2012, Ren et al., 
2013) and Roger Morris and others have suggested that LRP1 may act as a receptor for PrP 
(Taylor and Hooper, 2007, Parkyn et al., 2008). Indeed, recent evidence suggests that lipid 
rafts and LRP1 are required for prion-mediated toxicity of amyloid β oligomers (Rushworth 
et al., 2013). Multiple studies have used lipoprotein-deficient serum to ‘starve’ cultured cells 
and so reduce cholesterol levels (Narita et al., 1997, Hawes et al., 2010). Models of 
cholesterol depletion show disruption of cell membranes (Hao et al., 2001, Yang et al., 2012) 
and increased shedding of membrane proteins into the extracellular matrix and culture 
medium (Murai et al., 2011). Furthermore, limiting the availability of exogenous cholesterol 
can alter cell adhesion and motility by disrupting lipid rafts which contributes to loss of 
adhesion proteins (Jeon et al., 2010, Baumgartner et al., 2014). 
The LRPs constitute a family of receptors with multiple functions united by binding of 
lipoproteins (Strickland et al., 1995, Ye et al., 2012). Of note, LRP6 is involved in Caveolin-1 
signalling and regulates activity of Wnt-β-catenin (Tahir et al., 2013). This interaction is 
reinforced by the binding of LRP6 to Leucine rich repeat kinase 2 (LRRK2) which may help 
explain why LRRK2 mutations produce neurodegeneration in Parkinson’s disease (Berwick 
and Harvey, 2012). Interactions between LRP6 and Wnt are also implicated in tumorigenesis 
(Li et al., 2004) with increased LRP6 expression promoting cell proliferation. Similar to LRP1, 
LRP8 acts as a canonical receptor for ApoE and was previously known as ApoE Receptor 2 
(ApoER2) (Jaeger and Pietrzik, 2008). LRP8 is predominantly expressed in the brain (Kim et 
al., 1996) and mutations in LRP8 have been identified in Alzheimer’s disease patients (Carter, 
2007).  
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1.4.3 Intracellular cholesterol trafficking and storage 
Following endocytosis via clathrin-coated pits cholesterol is trafficked through the 
endosomal-lysosomal system. Excess cholesterol is esterified in the Endoplasmic Reticulum 
(ER) by the action of acyl-CoA: cholesterol acyltransferase (ACAT) enzymes and stored as 
cytoplasmic lipid droplets and in lysosomes (Tabas, 1995, Chang et al., 1997). When 
additional cholesterol is required esters are hydrolysed by lysosomal acid lipase, encoded by 
LIPA (Goldstein et al., 1975, Koch et al., 1981), and exported from lysosomes by the 
sequential action of Npc1 and Npc2 (Vance, 2010). Loss of function of either Npc1 or Npc2 
causes accumulation of cholesterol in lysosomes, with the gene names deriving from their 
pivotal role in invariably fatal Niemann-Pick type C neurodegenerative disease (Sturley et al., 
2004). Following export from lysosomes free cholesterol is transported to either the Trans 
Golgi Network (TGN) (Coxey et al., 1993), from where it is subsequently recycled to the 
plasma membrane or the ER (Ikonen, 2006). Cholesterol is also trafficked to mitochondria 
(Kennedy et al., 2012) where it is used for specialised tissue dependent processes including 
production of bile acids (Li and Chiang, 2014) and steroid hormones (Issop et al., 2013). 
Recent evidence indicates that accumulation of cholesterol in mitochondria may influence 
progression of Alzheimer’s disease (Barbero-Camps et al., 2014). 
Perturbations of intracellular cholesterol trafficking have been previously studied in prion 
disease. Notably, work by Clive Bate and Alun Williams has demonstrated that ACAT 
inhibitors increased toxicity in prion infected GT1 cells (Bate et al., 2008), whilst work by Gilch 
et al has shown that knockdown of Npc1 in prion-infected N2a cells decreased levels of PrPSc 
(Gilch et al., 2009). Expression of the GTPase Arf6 (ADP-ribolysation factor 6) has been shown 
to alleviate both cholesterol and sphingolipid accumulation following Npc1 ablation 
(Schweitzer et al., 2009) and functions in endosomal recycling. Arf6 is thought to be involved 
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in clathrin-independent endocytosis of PrPC (Kang et al., 2009), although expression of 
constitutively active Arf6 led to accumulation of PrPC in large intracellular vacuoles. 
1.4.4 Cholesterol export and degradation 
Cholesterol does not readily cross the blood brain barrier and instead a highly efficient 
recycling system operates in the CNS to maintain cholesterol levels (Dietschy, 2009). 
Cholesterol has a half-life of approximately six months in the brain (Andersson et al., 1990) 
and is eventually metabolised and excreted across the blood brain barrier for degradation in 
the liver (Pfrieger, 2003). Levels of CNS cholesterol metabolites in the periphery may be of 
use as indicators of neurological disease (Hughes et al., 2013). 
High levels of cholesterol activate nuclear liver X receptors (LXRs), transcription factors which 
regulate multiple aspects of cholesterol homeostasis in response to increased levels of sterol 
metabolites (Peet et al., 1998). Two LXRs are currently known, LXRα which is a canonical 
oxysterol sensor in the liver (Pawar et al., 2003) and LXRβ first discovered in the lab of Jan-
Åke Gustafsson which is found in the brain and other tissues (Warner and Gustafsson, 2015). 
LXRs act to prevent cellular accumulation of cholesterol (Ulven et al., 2004) and activate 
several pathways to induce cholesterol efflux (Gabbi et al., 2014). Of particular interest to 
this project LXRs regulate the expression of ATP-Binding Cassette Transporter A1 (ABCA1) 
which in turn exports cholesterol from cells (Jasmin et al., 2014). Expression of ABCA1 is 
stimulated not only by LXRs but also retinoic acid receptors and peroxisome proliferator-
activated receptors which can form an amplification loop for ABCA1 expression (Jiang et al., 
2012). Negative regulation of ABCA1 occurs following serum depletion and is mediated by 
several molecules including SREBP2 (Zeng et al., 2004), unsaturated fatty acids (Mauerer et 
al., 2009), and the non-sterol mevalonate pathway intermediate geranylgeranyl 
pyrophosphate (Gan et al., 2001). A deficit in ABCA1 expression and activity is associated 
with impaired vesicular traffic from the Golgi to the plasma membrane (Zha et al., 2003, Lin 
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et al., 2009). Although not itself located in lipid rafts (Oram and Heinecke, 2005) ABCA1 
dissociates cholesterol from rafts allowing for transport across cell membranes to external 
acceptors including Apolipoprotein A1 (ApoA1) (Boadu et al., 2012). Cholesterol efflux to 
ApoA1 enables the formation of high density lipoprotein molecules (HDL) (Plump et al., 1994) 
and impaired ApoA1 function can be disease causing in blood vessels (Plump et al., 1997, 
Smith, 2010). ApoA1 is not synthesised in the CNS, but can cross the blood brain barrier to 
incorporate into CNS lipoproteins (Pitas et al., 1987, Karten et al., 2006). In a mouse model 
lacking neuronal ABCA1 Karasinska et al demonstrated decreased brain cholesterol alongside 
increased cholesterol uptake from plasma HDL (Karasinska et al., 2009) potentially indicating 
perturbed tight junctions in the blood brain barrier. Prion infection is known to increase 
ABCA1 expression in infected cells which in turn may increase levels of PrPC and PrPSc (Kumar 
et al., 2008). This effect is intriguing as the cholesterogenic transcription factor SREBP2 is 
upregulated following prion infection (Bach et al., 2009) yet has been shown to negatively 
regulate transcription of ABCA1 in response to sterol depletion (Zeng et al., 2004). Recent 
work from the lab of Andy Hill shows that increased ABCA1 expression following prion 
infection was associated with reduced cholesterol efflux from cells and enhanced 
internalisation of ABCA1 (Cui et al., 2014). These effects could be reversed by increasing 
expression of ABCA1 and loading cells with cholesterol suggesting that prion replication may 
be inversely tied to cholesterol metabolism.  
Cholesterol can be experimentally depleted from cell membranes using small molecules. The 
bacteria-derived polyene antibiotic filipin III binds tightly to cholesterol and has been shown 
to disrupt lipid rafts (Schnitzer et al., 1994). Treating prion infected cells with filipin has been 
shown to impair PrP endocytosis and induce cellular PrP release, effectively ‘curing’ prion 
infection (Marella et al., 2002). The authors attributed the curing effect to release of PrPC 
which deprived PrPSc of a substrate for replication. Furthermore this study underscored the 
importance of cholesterol-rich raft domains for PrP trafficking and surface presentation. 
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Cyclodextrins are macrocyclic molecules which contain an internal pocket (Lopez et al., 
2011). Cyclodextrins exhibit various properties which has led to intensive research into their 
potential use for drug delivery (Gidwani and Vyas, 2014). In the context of this thesis the 
term cyclodextrins refers to hydrophilic molecules with a highly hydrophobic binding pocket. 
Cyclodextrins sequester cholesterol from plasma membranes into the hydrophobic pocket 
(Lopez et al., 2011) and methyl-β cyclodextrin (MβCD) is frequently used experimentally to 
deplete cellular cholesterol (Nicholson and Ferreira, 2009, Onodera et al., 2013). In 2009 
cyclodextrin analogues were demonstrated to exert anti-prion effects (McEvoy and 
McMahon, 2009). Interestingly these effects were not attributed to cholesterol depletion 
and the authors instead suggested that cyclodextrins may act as chaperones to ensure 
correct folding of PrPC. Similarities in the mechanism of action of the cyclodextrins used and 
heparin were also highlighted. Heparin and other glycosaminoglycans have been previously 
shown to exert anti-prion activity (Bazar et al., 2011, Vieira et al., 2014) putatively by 
interfering with interactions between PrP and the cell membrane. Although growing 
evidence suggests lipid rafts are not the site of prion conversion (Borchelt et al., 1992, 
Marijanovic et al., 2009) the availability of PrPC as a substrate for prion replication remains 
tightly linked to membrane cholesterol. Altered cholesterol efflux, whether mediated by 
small molecules or gene silencing, would be expected to influence prion replication. 
Excess CNS cholesterol is metabolised to allow for secretion to the periphery. The brain-
specific enzyme CYP46A1 converts excess cholesterol to 24S-OH cholesterol allowing for 
excretion across the blood brain barrier (Russell et al., 2009). Sterol metabolites are then 
transported to the liver for degradation to bile salts (Li and Chiang, 2014). The presence of 
sterol metabolites in plasma has drawn interest as an indicator of Alzheimer’s disease 
(Ogundare et al., 2010, Zuliani et al., 2011) and disrupted CNS cholesterol metabolism may 
provide a potential early biomarker of prion disease which could be detected before blood-
borne PrPSc. 
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1.5 Rationale and Aims 
A growing body of literature indicates that host-encoded cellular factors influence prion 
propagation. In this thesis I will describe my work characterising the effects of cholesterol on 
prion replication and outline a potential mechanism for these effects. Primarily this work is 
focused on the effects of silencing Hmgcr, Dhcr24, Npc1 and Npc2. These genes allow for 
examination of both the effects of disrupted cholesterol synthesis and trafficking on prion 
replication. Beyond effects on levels of PrPSc we also examined the association of PrPC with 
lipid rafts in order to investigate a potential mechanism through which cholesterol 
perturbation affects prion replication. The aim of this project is to investigate the effect of 
depletion of Hmgcr, Dhcr24, Npc1 and Npc2; and subsequent changes in cholesterol, on 
prion propagation.  
 I will also outline a pilot study designed to identify cellular factors underlying susceptibility 
of cultured cells to different prion strains. Subcloning the CAD5 cell line, which propagates 
both RML and 22L prions, yields rare variant clones which exclusively propagate a single prion 
strain. This project aimed to identify cellular factors underlying cellular susceptibility to 
different prion strains by isolation of rare variant subclones and subsequent analysis of these 
subclones. As a pilot study this work establishes methods for high throughput screening of 
subclones and gives an indication of the cohort size required to examine differences between 
rare variant subclones propagating different prion strains.  
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CHAPTER 2 METHODS 
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2.1 Cell lines and culture 
Our primary cell line for experimental use is N2a-PK1-S7 (S7). This cell line was derived from 
the N2a parent line, is highly susceptible to infection with RML prions, and has been used to 
generate the chronically infected cell line N2a-PK1-IPKS7 (iS7) (Klohn et al., 2003). LD9 cells 
were derived from the murine fibroblast cell line L929 (Mahal et al., 2007). CAD5 cells were 
derived from mouse neuroblastoma tissue (Qi et al., 1997). A summary of cell lines and 
culture conditions is shown in Table 2.1. OptiMEM is supplemented with 10% Foetal Calf 
Serum and 1% Pen/Strep (OFCS,Gibco). Alternatively OptiMEM was supplemented with 10% 
Bovine Growth Serum (HyClone) and 1% Pen/Strep (OBGS). Minimum Essential Medium 
(Sigma) is supplemented with 10% Foetal Calf Serum and 1% Pen/Strep (MEME). Dulbecco’s 
Modified Essential Medium (Gibco) is supplemented with 10% Foetal Calf Serum and 1% 
Pen/Strep (DMEM). 
Table 2.1 A summary of cell lines used in this project. 
Name Species Culture conditions 
N2a-PK1-S7 (‘S7’) Mouse OFCS, 37°C 5% CO2 
N2a-PK1-IPKS7 (‘iS7’, RML 
infected) 
Mouse OFCS, 37°C 5% CO2 
N2a-PK1-11 (‘PK1-11’) Mouse OFCS, 37°C 5% CO2 
N2a-PK1-R33 (‘R33’) Mouse OFCS, 37°C 5% CO2 
CAD5 Mouse OBGS, 37°C 5% CO2 
L929-LD9 (‘LD9’) Mouse MEME, 37°C 5% CO2, requires trypsin to 
split 
RetroPack PT67 Mouse  DMEM, 37°C 5% CO2, viral packaging 
cells 
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2.2 Scrapie Cell Assay  
The Scrapie Cell Assay (SCA) is a method for detecting infectious prion titres in cultured cells 
(Klohn et al., 2003). The SCA has been previously used to characterise the response of cell 
lines to different prion strains (Mahal et al., 2007). Multiple splits are used to induce 
propagation and infection can be determined through an Enzyme Linked ImmunoSpot Assay 
(Elispot). The SCA has been fully automated and allows for high throughput determination 
of infectious titres. 
The SCA is performed in 96-well plates. Twenty thousand cells per well were plated in 300µl 
of the normal culture medium for the cell type (see Table 1), allowed to adhere for 16 hours 
at normal culture conditions (37°C, 5.0% CO2) and then media was replaced with 300µl of 
prion-containing sample (infected brain homogenate diluted in culture media). A 10-3 
dilution of homogenate typically saturated the elispot assay necessitating the use of lower 
concentrations. In the automated version of the SCA assay, a 10-5 dilution was used for each 
homogenate. Control cells were treated with uninfected media. Cells were passaged once 
every three days at a 1:8 split (cells were resuspended in wells and 40µl was transferred to a 
new well containing 260µl of new media). Following growth to confluence after the 3rd split 
the PrPSc content of cells was assessed using the Elispot protocol. A schematic of the SCA is 
shown in Figure 2.1. 
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Figure 2.1 The Scrapie Cell Assay 
 Cells were plated in 96-well plates as described above (part A). After 16 hours growth cell 
culture medium was removed and replaced with prion brain homogenate diluted in cell 
culture media (typically to 10-5 of the stock concentration) and cells were allowed to continue 
growing for a further 2 days (3 days total after initial plating, part B). Cells were passaged 
every 3 days in 1:8 split ratios (part C), and samples collected for Elispot (orange, see section 
2.2.1) and Trypan Blue (blue, see section 2.2.1 (b)) assays at predetermined points (part D). 
Passage and sample collection was performed at multiple points, typically at the post-3rd and 
post 4th passages. Each subsequent split diluted out the initial prion homogenate while 
allowing cells to grow and propagate PrPSc without reaching confluence.  
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2.2.1 Elispot determination of PrPSc-positive cells 
The Elispot protocol assesses the PrPSc content of cells in a 96-well PVDF membrane plate 
(Corning) format. Plates were activated with 70% ethanol, washed twice with PBS and fluids 
were removed by applying a vacuum. Cells were then seeded onto the plates at a density of 
20000 cells per well unless indicated otherwise. When fewer cells were seeded, non-infected 
control cells were added to a total of 20000 cells. Plates were then dried for one hour at 50°C 
and stored in the fridge (2-8°C) until further use. Plates were incubated with 60µl Proteinase 
K (PK, Roche), diluted to 10-4 in lysis buffer (50mM Tris.HCl, 150mM NaCl, 0.5% Na 
deoxycholate, 0.5% Triton X-100 in dH2O, pH 7.4) for 1 hour at 37°C then washed twice with 
PBS. PK digest was stopped by 120µl of 1mM phenylmethanesulfonylfluoride (PMSF) for 10 
minutes. Tris-guanidinium thiocyanate (GTC, 3M, 120µl/well) was then added and plates 
incubated for 20 minutes. GTC denaturation was followed by seven washes with PBS, 
discarding each wash into 2M NaOH. To block unspecific binding sites, wells were incubated 
with 120µl superblock (Pierce) for 1 hour. Plates were incubated at room temperature for 1 
hour with 60µl primary antibody (mouse anti-PrP ICSM18, D-GEN, 1:5000 in TBST (10mM 
Tris-HCl, 150mM NaCl, 0.1% Tween 20 (v/v)), pH 7.4/1% non-fat milk powder). Plates were 
then washed five times with TBST and incubated with 60µl secondary antibody (goat anti-
mouse-IgG1 AP, Cambridge Bioscience, 1:8000 in 1xTBST/1% non-fat milk powder) for 1 hour 
at room temperature. Wells were washed five times with TBST, the underdrain of the plates 
removed and membranes dried. Plates were then incubated with 54µl of alkaline 
phosphatase colour reaction (BioRad) for approximately 30 minutes at room temperature 
before rinsing with dH2O twice and drying. Plates were analysed using plate reader software 
(Bio-Sys) to quantify the number of infected cells as mean and standard deviation. Individual 
wells of a 96-well plate were counted as technical repeats, 12 technical repeats were 
performed for each biological repeat. At least 3 biological repeats were performed for each 
condition tested. 
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2.2.1 (a) Chronically prion infected cell Elispot 
In addition to examining prion infection in the SCA the Elispot assay can be used to determine 
prion replication in chronically infected cells. Unlike in the SCA a population of chronically 
infected cells is expected to be uniformly infected and as such a lower cell seeding density 
was required to prevent plate reader saturation (20000 spots is far beyond the capabilities 
of our current system). Typically plates were seeded with 1000 or 2500 chronically infected 
cells per well buffered to 20000 cells per well total with uninfected cells. In experiments 
where the buffer cells were omitted the concentration of PK in the Elispot assay was reduced 
by half to 1/20000 in lysis buffer to prevent over-digestion of PrPSc. 
2.2.1 (b) Trypan Blue assay 
As cell counting and dilution carries an inherent error the Trypan Blue assay was used to 
determine the number of cells seeded per Elispot. A volume approximately equal to 1000 
cells was seeded on elispot plates as per the PrPSc quantification assay above. Dry plates were 
washed with 0.04% Trypan Blue in PBS and immediately vacuumed, then washed twice again 
on the vacuum with PBS. Plates were then dried in a hood and read using a Bio-Sys plate 
reader as above. 
2.3 Confocal microscopy 
Images were captured using a Leica 710 confocal microscope and Zen software; where 
required co-localisation and quantification was assessed using Volocity software. Cells were 
grown to near confluence in 4- or 8-well chamber slides (Corning) and fixed for 
immunolabeling as described below. 
2.3.1 Fixation conditions  
Cells were incubated with 4% paraformaldehyde (PFA) for 20 minutes, washed with PBS and 
incubated with 0.04% Triton X-100 for 15 minutes to permeabilise cells. Cells were washed 
and stored in PBS. Alternative permeabilisation conditions were used to improve the 
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detection of PrP deposits in fixed cells. Incubation of fixed cells for one minute at room 
temperature with acetone (Ac) solubilises and strips neutral lipids (Urist et al., 1997) and 
reveals previously unseen PrP deposits on the basement adherent membrane of cells 
(Marbiah et al., 2014). To reveal prion infection associated PrP  deposits (PrPd) cells were 
fixed with 4% PFA for 12 minutes, incubated with pre-chilled acetone for 30 seconds, washed 
with PBS, and then incubated with 3M guanidinium thiocyanate (GTC) for 10 minutes to 
denature proteins within fixed cells to better facilitate antibody binding. Slides were then 
washed three times with PBS before a further two washes with fresh sterile PBS to avoid GTC 
cross-contamination which could denature antibodies. Alternatively, five minutes incubation 
with 100µg/ml digitonin was used to permeabilise BODIPY and filipin treated cells in place of 
Triton X-100 or acetone/GTC (see below). The fixation and permeabilisation used for each 
image is given in the relevant figure legend. 
2.3.2 Immunofluorescence 
Secondary antibodies conjugated to Alexa Fluor 488, 568 and 633 were obtained from 
Molecular Probes. Highly cross-adsorbed preparations of these antibodies were used for 
dual labelling experiments. Primary antibodies were purchased from D-Gen, Sigma Aldrich, 
CST and Santa Cruz. 
Following permeabilsation cells were incubated overnight with primary antibody in sterile 
filtered PBS:Superblock (4:1) at 4°C. Primary antibody concentrations were typically ranged 
between 1:500 and 1:2000 dilutions of the manufacturers stock. Slides were washed once 
with sterile PBS and incubated with the relevant secondary antibodies and DAPI (1:10000 
dilution of 4µg/ml stock) in PBS:Superblock for 1 hour at room temperature in the dark. 
Labelled slides were washed once with PBS and stored at 4°C in 0.1% sodium azide (v/v) in 
PBS until microscopy. 
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2.3.3 Tracking cholesterol trafficking with BODIPY FL cholesterol 
BODIPY FL cholesterol (Molecular Probes), a cholesterol analogue, was used to investigate 
lipid trafficking. Live cells were incubated with 1 µM BODIPY FL cholesterol in their normal 
growth media and cells were then fixed using PFA/digitonin as described above and antibody 
labelled as necessary. Although 1 hour incubations with BODIPY FL cholesterol have been 
previously used (Sankaranarayanan et al., 2011) we found more evident and specific staining 
using overnight incubation (~16 hours) under normal culture conditions (37°C, 5.0% CO2).  
2.3.4 Filipin labelling  
Although BODIPY FL cholesterol is a useful tool to track cholesterol trafficking it does not 
provide information on cholesterol levels within cells. Filipin is a sterol-binding protein and 
so can act as a direct measure of cholesterol levels in cells. Due to artefacts in fixed cells with 
our standard fixation and permeabilisation protocols fixation to visualise filipin required re-
optimisation. Fixation was optimised to a 10 minute fix with 4% PFA followed by 10 minutes 
incubation with 50µg/ml digitonin to permeabilise cells. Fixed permeabilised cells were 
incubated for 1 hour with 20µg/ml filipin in the dark at room temperature. Labelled cells 
were washed once with PBS and then imaged with a Zeiss 510 confocal using ultraviolet 
excitation and a long pass bandwidth filter.  
2.3.5 Live cell imaging  
Lysosensor Green DND-189 (‘Lysosensor’, Life Technologies) was used to identify changes in 
intracellular pH in live cells. Cells were incubated with 100nM Lysosensor in growth media 
for 30 minutes at 37°C with 5% CO2, before replacing with media containing 10mM HEPES  
(pH 7.4) immediately prior to imaging to preserve pH in the absence of CO2. Imaging sessions 
were limited to 30 minutes at which point cells lost viability. To label the endocytotic 
pathway Dextran Texas Red (Life Technologies) was used. Cells were incubated overnight 
(>16 hours) with 100µg/ml Dextran Texas Red before washing once with growth media and 
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incubating with Lysosensor as above. Overnight incubation ensured Dextran Texas Red 
accumulated in lysosomes prior to imaging (Jaiswal et al., 2002). 
2.4 Assessment of target manipulation on cells 
Pharmacological and genetic methods were used to perturb lipid pathways and assess 
resulting effects on PrPSc in cells. 
2.4.1 Small inhibitor/drug treatment 
Various small inhibitors and biologically active molecules were used to deplete cholesterol 
from cells. Where stock concentrations were made in DMSO stocks were made at 1000-fold 
the highest working dilution to reduce the likelihood of off-target vehicle effects. Cells were 
seeded in 96 well plates at a density of 15000 cells/well and grown overnight. Media was 
removed and replaced with a serial dilution of drug treatment in normal cell media. After 3 
days growth cells were harvested for their intended use. Stocks of Lovastatin (Santa Cruz) 
and Simvastatin (Sigma) were made in DMSO and used to inhibit cholesterol synthesis. 
Methyl-β cyclodextrin (MβCD, Sigma) is a highly hydrophilic molecule which sequesters 
cholesterol from cell membranes (Kilsdonk et al., 1995, Lopez et al., 2011) and was diluted 
directly in cell culture medium. 
2.4.1 (a) Determination of cell viability 
Cell viability following drug treatment was assessed using the CellTitre Glo assay (Promega) 
which measures ATP levels in cells by mono-oxygenation of luciferase. Media was removed 
from cells treated in 96 well plates as above and replaced with 80µl CellTitre reagent mixture 
prepared according to the manufacturer’s instructions. The plate was then transferred to a 
Tecan plate reader and incubated at room temperature for 10 minutes, shaken at 1mm 
amplitude for 2 minutes and then luminescence recorded. Luminescence was normalised to 
vehicle treated cells to give percentage cell viability relative to control. 
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2.4.2 siRNA screening 
Custom DICER substrate siRNA (DsiRNA) were purchased from Integrated DNA Technologies 
(IDT). DsiRNAs are double-stranded RNA molecules that were delivered to cells using 
DharmaFECT lipid transfection. At least 3 DsiRNAs were designed per target and tested for 
efficacy of gene knockdown. Silencing RNA duplexes are summarised in Table 2.2. 
Knockdown of target expression was quantified using qPCR (see below). Reverse transfection 
of cells with DsiRNAs and DharmaFECT 3 (D3, Thermo Fisher) was established as a standard 
gene silencing protocol. DsiRNA and D3 were mixed in 100µl OptiMEM and incubated at 
room temperature for 20 minutes. OFCS was then added and the reagents mixed 1:1 with a 
1x105 cells/ml cells suspension to give a final DsiRNA concentration of 20nM and D3 
concentration of 0.13% for N2a-derived cell lines. 300µl of this mix was plated per well of a 
96 well plate whilst 550µl was plated per well of an 8 well chamber slide (Corning). Control 
cells were treated with NC1 non-silencing DsiRNA (IDT). Cells were grown for 3 days, at which 
point we observed greatest gene silencing as assessed by qPCR, and then fixed/infected as 
described above depending on intended use.  
Where gene knockdown was required for longer periods, such as to ensure protein turnover 
prior to confocal imaging, cells were subject to double knockdown. Here cells were split into 
media containing the same proportion of DsiRNA/D3 mix following the initial 3 day 
incubation. Cells were then grown for a further 3 days before being used as per the single 
knockdown protocol outlined above. 
2.4.2 (a) Transient gene knockdown in primary cortical neuron cultures 
Preparations of E17 primary mouse cortical neurons were kindly provided by Dr Silvia Purro. 
Due to key differences in culture technique between primary cultures and cell lines our siRNA 
transfection protocol required adaptation. Primary neurons seeded at 5x105 cells per well in 
6 well plates (Corning) were transfected at 8 days in vitro (DIV) by replacing culture medium 
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(CMII, Neurobasal medium containing 2% B27, 1mM pyruvate, 2mM glutamine and 1% 
Pen/Strep, all Life Technologies) for 6 hours with 2ml conditioned medium containing siRNA-
Dharmafect 4 complexes prepared as above at a final concentration of 2µl/ml siRNA and 
0.7µl/ml Dharmafect 4. Culture medium was replaced after 6 hours with 2ml fresh 
conditioned media. Conditioned media was CMII obtained from 10cm dishes of 
untransfected primary neurons. The effect of gene silencing was assessed 3 days later at 
11DIV. For Western blotting and Optiprep gradients (see below) cells were lysed on ice for 
20 minutes with 250µl TNET buffer containing 1µl/ml protease inhibitor cocktail (Pierce) per 
well.
65 
 
Table 2.2 DsiRNA designs. Multiple DsiRNA duplexes were designed per target for experimental control purposes.  
Target DsiRNA Sense sequence Antisense sequence 
Npc1 
1 5'-rGrCrArGrCrArGrGrCrUrCrCrUrGrGrUrGrGrArUrUrCrUAA 5’-rUrUrArGrArArUrCrCrArCrCrArGrGrArGrCrCrUrGrCrUrGrCrArG 
2 5'-rCrCrArArUrArCrArUrGrCrCrUrGrUrCrArUrUrCrArCrGTG 5'-rCrArCrGrUrGrArArUrGrArCrArGrGrCrArUrGrUrArUrUrGrGrUrU 
3 5'-rCrUrArCrCrArGrArGrArGrArUrGrArGrCrGrUrCrUrUrCAG 5'-rCrUrGrArArGrArCrGrCrUrCrArUrCrUrCrUrCrUrGrGrUrArGrGrU 
4 5'-rGrGrArGrUrArCrUrUrUrGrArCrArArGrCrArCrUrUrUrGGG 5'-rCrCrCrArArArGrUrGrCrUrUrGrUrCrArArArGrUrArCrUrCrCrUrU 
5 5'-rCrCrGrUrGrArCrArCrUrGrCrArGrGrArCrArUrCrUrGrUGT 5'-rArCrArCrArGrArUrGrUrCrCrUrGrCrArGrUrGrUrCrArCrGrGrUrU 
6 5'-rCrCrArGrUrArGrArArArCrCrUrCrArUrCrUrUrGrGrGrUAC 5'-rGrUrArCrCrCrArArGrArUrGrArGrGrUrUrUrCrUrArCrUrGrGrUrA 
Npc2 
1 5'-rCrCrArCrCrArCrCrUrArGrCrArCrCrArCrUrUrGrArGrGAG 5'-rCrUrCrCrUrCrArArGrUrGrGrUrGrCrUrArGrGrUrGrGrUrGrGrUrU 
2 5'-rGrGrArGrArGrGrGrArGrGrArArGrArGrGrCrUrGrUrGrGCT 5'-rArGrCrCrArCrArGrCrCrUrCrUrUrCrCrUrCrCrCrUrCrUrCrCrUrU 
3 5'-rGrCrCrArUrArUrGrArUrGrArArCrArGrArArUrUrUrCrAAG 5'-rCrUrUrGrArArArUrUrCrUrGrUrUrCrArUrCrArUrArUrGrGrCrArC 
4 5'-rGrGrArUrGrGrCrUrUrCrCrCrArGrArGrUrCrUrUrCrUrGGC 5'-rGrCrCrArGrArArGrArCrUrCrUrGrGrGrArArGrCrCrArUrCrCrUrU 
 
 
 
 
1 5'-rGrArArGrGrArGrUrUrGrCrCrUrUrGrGrArGrUrUrUrCrACC 5'-rGrGrUrGrArArArCrUrCrCrArArGrGrCrArArCrUrCrCrUrUrCrArU 
2 5'-rGrGrCrArGrArArUrCrArCrCrUrCrArUrCrCrArUrUrUrGGC 5'-rGrCrCrArArArUrGrGrArUrGrArGrGrUrGrArUrUrCrUrGrCrCrUrU 
3 5'-rCrArArGrCrArUrGrGrUrGrUrUrCrUrGrGrGrUrCrCrCrAGC 5'-rGrCrUrGrGrGrArCrCrCrArGrArArCrArCrCrArUrGrCrUrUrGrGrA 
4 5'-rCrUrArGrArArArGrCrUrGrArArUrUrGrGrCrUrGrUrUrGCT 5'-rArGrCrArArCrArGrCrCrArArUrUrCrArGrCrUrUrUrCrUrArGrCrC 
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Dhcr24 
 
 
 
 
 
 
 
5 5'-rCrCrArArGrArUrCrUrCrCrCrUrCrCrUrGrArArGrCrUrGAC 5'-rGrUrCrArGrCrUrUrCrArGrGrArGrGrGrArGrArUrCrUrUrGrGrGrA 
6 5'-rGrCrArUrGrArGrGrCrArGrCrUrGrGrArGrArArGrUrUrUGT 5'-rArCrArArArCrUrUrCrUrCrCrArGrCrUrGrCrCrUrCrArUrGrCrArG 
7 5'-rGrGrGrArGrArUrGrArArGrCrArGrArGrCrUrCrUrArCrGTG 5'rCrArCrGrUrArGrArGrCrUrCrUrGrCrUrUrCrArUrCrUrCrCrCrUrU 
8 5'-rCrCrUrCrUrArGrArGrUrCrCrArCrUrGrArGrUrCrArCrAAT 5'-rArUrUrGrUrGrArCrUrCrArGrUrGrGrArCrUrCrUrArGrArGrGrArG 
9 5'-rGrUrCrUrUrArArGrArCrGrUrUrGrGrGrArArArGrCrCrUCG 5'-rCrGrArGrGrCrUrUrUrCrCrCrArArCrGrUrCrUrUrArArGrArCrArG 
10 5'-rCrArArGrArArGrArCrCrCrArUrArArGrArArCrArUrCrATG 5'-rCrArUrGrArUrGrUrUrCrUrUrArUrGrGrGrUrCrUrUrCrUrUrGrUrA 
11 5'-rCrUrCrUrGrArGrGrUrCrCrUrUrCrUrGrCrCrUrUrGrUrUGA 5'-rUrCrArArCrArArGrGrCrArGrArArGrGrArCrCrUrCrArGrArGrGrC 
12 5'-rGrUrCrArCrArUrUrArGrCrCrUrCrArGrGrUrUrArGrUrGTT 5'-rArArCrArCrUrArArCrCrUrGrArGrGrCrUrArArUrGrUrGrArCrUrC 
Hmgcr 
1 5'-rCrCrArArUrGrUrCrArUrCrUrUrGrCrUrArArArUrUrCrATG 5’-rCrArUrGrArArUrUrUrArGrCrArArGrArUrGrArCrArUrUrGrGrUrU 
2 5'-rGrCrArUrArUrCrCrCrArGrCrUrUrArCrArArArUrUrGrGAA 5’-rUrUrCrCrArArUrUrUrGrUrArArGrCrUrGrGrGrArUrArUrGrCrUrU 
3 5'-rGrGrArCrUrArArCrArUrGrCrArArUrCrUrGrUrGrArArUTA 5'-rUrArArUrUrCrArCrArGrArUrUrGrCrArUrGrUrUrArGrUrCrCrUrU 
4 5'-rGrArArCrCrArGrArArGrCrUrUrUrCrGrUrCrArGrUrArGAG 5'-rCrUrCrUrArCrUrGrArCrGrArArArGrCrUrUrCrUrGrGrUrUrCrCrU 
5 5'-rCrArArGrGrArGrCrArUrGrCrArArArGrArCrArArUrCrCTG 5'-rCrArGrGrArUrUrGrUrCrUrUrUrGrCrArUrGrCrUrCrCrUrUrGrArA 
6 5'-rGrGrArCrArUrUrGrArGrCrArArGrUrGrArUrUrArCrCrCTG 5'-rCrArGrGrGrUrArArUrCrArCrUrUrGrCrUrCrArArUrGrUrCrCrArU 
7 5'-rCrArGrCrCrArArGrGrUrGrGrUrGrArGrArGrArGrGrUrGTT 5'-rArArCrArCrCrUrCrUrCrUrCrArCrCrArCrCrUrUrGrGrCrUrGrGrA 
8 5'-rGrGrGrUrCrArArGrArUrGrArUrUrArUrGrUrCrUrUrUrAGG 5'-rCrCrUrArArArGrArCrArUrArArUrCrArUrCrUrUrGrArCrCrCrUrU 
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2.4.3 qPCR 
Real-time quantitative polymerase chain reaction (qPCR) was performed to validate the 
efficiency of gene knockdown following transfection using PrimeTime qPCR assays (IDT). 
Transfected cells were grown to confluence and a sample of 105 cells lysed using Cell-to-CT kit 
(Ambion/Life Technologies) according to the manufacturer’s instructions. Complementary DNA 
(cDNA) was generated using reverse transcription (RT) PCR of cell lysates according to the 
manufacturer’s instructions.  Briefly, cell pellets were lysed by incubating in 50µl Ambion lysis 
buffer containing 2U DNase I for 8 minutes at room temperature. Ten microlitres of lysate was 
added to 40µl of Ambion RT master mix and heated at 37°C for 1 hour followed by 95°C for 5 
minutes.  qPCR was then performed using the Ambion Taqman system as described by the 
manufacturer in conjunction with custom PrimeTime qPCR assays purchased from IDT. Per 20µl 
reaction 10µl ABI master mix, 2µl PrimeTime assay, 1µl housekeeping probe (mouse β-actin, 
4µM), 1µl mixed housekeeping primers (at 9µM each) and 2µl nuclease free water were 
combined with 4µl RT reaction in a single well of an optical plate (Applied Biosystems). The 
specific PrimeTime primers and probes used for each target are shown in Table 2.3. Where 
possible PrimeTime assays were designed to target exon-exon boundaries and so prevent 
amplification of genomic DNA. However, this was not possible for murine Prnp. A custom, 5’ VIC-
tagged probe and primer set was designed for murine β-actin for use as a housekeeping gene. 
qPCR was run on a FAST 500 thermocycler using the manufacturer’s standard protocol with 40 
cycles of amplification. Relative gene expression was then calculated using the ΔΔCT method 
where: 
  𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑔𝑒𝑛𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 100 × 2−∆∆𝐶𝑇 
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Table 2.3 Gene targets and the relevant PrimeTime assay qPCR primers and probes designed 
for each. All probes were labelled with 6-FAM/ZEN/IBFQ 5’-3’ as described by IDT, assays were 
designed to deliver a primer to probe ratio of 2.0. 
Target  Sequence 
Prnp 
Forward primer CTTCCTCATCTTCCTGATCGTG 
Probe CTTGTTCCTTCGCATTCTCGTGGTCT 
Reverse Primer GGGACACAGAGAAGCAAGAAT 
Npc1 
Forward primer TTTCTGATAACCCCAACCCC 
Probe AGTGGCCCCAATGTAAGTGTCATCTC 
Reverse Primer GTCAGCGGAGGTCTTAAGTATG 
Npc2 
Forward primer TCAACATCACCTTTACCAGCG 
Probe CACTCAGTCCCAGAACAGCACGG 
Reverse Primer TGATTCCACTCTTACAACCGTC 
Dhcr24 
Forward primer AGAACTACCTGAAGACAAACCG 
Probe CCCTGAGACACTACTACCACCGACA 
Reverse Primer GAAGAGGTAGCGGAAGATGG 
Hmgcr 
Forward primer GCCCTCAGTTCAAATTCACAG 
Probe TGCCATTCCACGAGCTATATTTTCCCTT 
Reverse Primer TTCCACAAGAGCGTCAAGAG 
β-Actin 
Forward primer ACCTCCTACAATGAGCTGCG 
Probe TCTGGGTCATCTTTTCACGGTTGGC 
Reverse Primer CTGGATGGCTACGTACATGG 
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2.4.4 Western blotting 
Western blots were performed alongside qPCR to validate the knockdown efficiency of DsiRNA 
transfection and examine effects on other proteins. Transfected cells were grown to confluence 
in a 96-well plate and ~7×105 cells (10 wells) collected and pelleted. Pellets were lysed in radio 
immunoprecipitation assay (RIPA, 50mM Tris, 150mM NaCl, 0.5% sodium deoxycholate, 1% 
Triton (v/v), pH 7.4) buffer containing 0.4 µl benzonase and 1 µl protease inhibitor cocktail 
(Sigma) per millilitre and mixed 1:1 with 2× SDS Sample buffer (Novex) containing 4% 2-
mercaptoethanol before heating for 5 minutes at 100°C. Forty microlitres of each sample were 
then transferred to a 16% Tris/Glycine gel and run alongside SeeBlue Plus 2 ladder (Life 
Technologies) for 90 minutes at 200V in SDS/TRIS/glycine running buffer (pH 8.3). The gel was 
blotted onto PVDF membrane in Tris/glycine blotting buffer containing 20% methanol (v/v, pH 
8.5) at 35V for 180 minutes. Both running and blotting buffers were obtained as 10X solutions 
from Pierce. The membrane was blocked with 5% milk in PBST (PBS with 1:200 Tween-20 added) 
for 30 minutes and then incubated overnight at room temperature with the required primary 
antibody in PBST (typically at a 1:5000 dilution of manufacturer’s stock unless otherwise noted). 
Actin was used as a loading control: the membrane was cut between the protein of interest and 
actin using the ladder as a guide and blocked as above. The actin section of membrane was 
incubated overnight with mouse anti-actin (AbCam, 1:8000) and processed in parallel with the 
membrane section containing the protein of interest. Following overnight incubation the 
membrane was washed in PBST (3x5 minutes) and incubated with the relevant 
chemiluminescence-conjugated secondary antibody (typically 1:6500 in PBST, 1:10000 for actin) 
for one hour at room temperature. The membrane was then washed in PBST again as above, 
drained and incubated for 5 minutes with West Pico chemiluminescence substrate (Thermo 
Fisher) before draining and exposing to film (Biomax MR, Kodak) under a red safelight. For 
targets of a similar size to actin, including PrP, it was not possible to cut the membrane and label 
both simultaneously. Instead membranes were stripped and re-probed for actin to confirm 
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equal loading. Membranes were washed 3x1 minute with PBS and then incubated for 15 minutes 
with 5ml Restore Western blot stripping buffer (Sigma) at room temperature. Membranes were 
then again washed 3x1 minute with PBS and blocked with 5% milk/PBST as above before re-
probing with anti-actin. Western blotting was analysed using greyscale scanned JPEG images in 
ImageJ software. 
2.4.5 Amplex Red assay to determine cholesterol levels  
Quantification of cholesterol in cells can be assessed by filipin labelling but this did not allow for 
high throughput screening. The Amplex Red cholesterol assay (Invitrogen) allows for 
colorimetric measurement of cholesterol and cholesteryl ester levels within cells based on the 
oxidation of cholesterol to resurofin and quantifies cholesterol levels in 96-well plate format. 
Cells were transfected and grown as for Western blotting above. Confluent cells were washed 
once with PBS and then lysed using 200µM sucrose in TE buffer (100µl/well) before being diluted 
1:10 with Amplex Red reaction buffer. Fifty microlitres of diluted sample was transferred to a 
black-wall 96-well plate to which 50µl of Amplex Red master mix (prepared according to 
manufacturer’s instructions) was added. Samples were excited at 540nm with emission read at 
590nm at 10 minute intervals (up to 40 minutes) whilst incubating at 37°C. Peak signal was 
typically observed after 30 minutes incubation. 
2.4.6 Ultracentrifugation to isolate lipid rafts on Optiprep gradients  
Lipid rafts were isolated in a protocol adapted from the work of Waheed and Jones (2002). Cell 
pellets of 3 million cells were resuspended in 1ml of TNET buffer (50mM Tris-HCl, pH 7.4, 150mM 
NaCl, 5mM EDTA, 0.5% (v/v) Triton X-100, pH 7.4) containing 1µl/ml protease inhibitor cocktail 
(Sigma), incubated on ice for 20 min, and then homogenized by vortexing for 30 seconds. The 
cell lysate was adjusted to 35% Optiprep (Sigma, 1.5ml Optiprep, 1ml lysate) and overlaid with 
6ml of 30% Optiprep in TNET (3ml Optiprep, 3ml TNET) and then with 500μl of 5% Optiprep in 
TNET, in Beckman SW 41 tubes. Samples were centrifuged for 16 hours at 41000rpm (equivalent 
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to 207000 x g across samples) at 4 °C and fractionated from the top. The fractions 1-9 defined 
as 1ml fractions and further divided into 333µl fractions to better examine gradients. Aliquots 
of 333µl fractions were pooled to reconstitute a complete gradient of 1ml fractions (see Figure 
2.2). Collecting fractions in this way allowed for examination of the complete gradient as well as 
a more detailed look at the fractions immediately containing PrPC in optimisation experiments. 
SDS sample buffer containing 4% 2-mercaptoethanol was added to aliquots of each fraction of 
the gradient in equal parts and run on Western blot as described above (2.4.4). The cholesterol 
content of fractions was determined by Amplex Red assay as described above (2.4.5). Aliquots 
of each fraction were diluted 1:10 for the assay and fluorescence compared to a standard curve 
of cholesterol concentrations to quantify the concentration of cholesterol per sample. 
 
Figure 2.2 Formation of Optiprep gradients to isolate lipid rafts Following ultracentrifugation a 
continuous Optiprep gradient was formed. Fractions 1-9 were defined as 1ml each subsequently 
collected from the top of the gradient. To better examine insoluble proteins near the top of the 
gradient in some experiments fractions were collected at smaller volumes and aliquots pooled to 
reconstitute the original fractions.  
2.4.7 Cholera Toxin labelling of fractions 
Where required lysates were pre-incubated with biotinylated cholera toxin subunit B (CtxB-b) 
to label GM1 gangliosides and so identify raft-containing Optiprep fractions. Pellets of 3x106 cells 
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in 1.5ml Eppendorf tubes were resuspended in 500µl 10µg/ml CtxB-b in PBS and rocked for 45 
minutes at 4°C. Samples were then washed 3 times by centrifuging at 16000g for 5 minutes and 
resuspending the pellet in 500µl PBS. Washed samples were then run on Optiprep gradients as 
above (2.4.6). To visualise CtxB-b membranes were blocked overnight in 5% milk/PBST followed 
by 1 hour incubation with 1/10000 streptavidin-HRP (Life Technologies) in PBST. After washing 
with PBST 3 times for 5 minutes the membranes were incubated with West PICO and exposed 
to film as described (2.4.4). 
2.5 Subcloning  
Cells were plated at limiting dilutions (100-200 cells/plate) into 10cm petri dishes and allowed 
to grow for seven days. Monoclonal colonies were picked using a p20 pipette and transferred 
into single wells of a 96-well plate. To synchronise cell growth of distinct subclones, cells were 
split for 2-3 passages at approximately 70% confluence. Clones with very fast or very slow cell 
doubling rates were discarded.  
2.5.1 Cryopreservation of subcloned cells 
Subcloned cells were frozen in 96-well plates to preserve subcloned variations which may affect 
prion propagation. Clones selected for SCA were duplicated in 96-well plates and grown to 
confluence before cryopreservation. Confluent wells were re-suspended in 150µl of growth 
medium and then gently mixed with a further 100µl of growth medium, containing 30% DMSO 
to give a final DMSO concentration of 12%. To prevent degassing of media during freezing, 50µl 
sterile mineral oil (Sigma) was layered above the growth medium. Plates were sealed with 
Parafilm and immediately insulated by swaddling in tissue and placing in Styrofoam boxes. These 
boxes were then placed into a freezer overnight at -80°C. Frozen plates were removed from 
insulation and stored at -80°C until required. Selected clones were resurrected by rapidly 
thawing the entire plate in a 37°C water bath. Plates were then cleaned externally with 70% 
ethanol and placed into a tissue culture MSC, Parafilm was removed and discarded and the 
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mineral oil layer carefully removed from wells by pipetting. Fifty microlitres of fresh growth 
media was added to wells and the entire plate was then placed into standard tissue culture 
conditions for approximately 16 hours. After cells adhered the medium was removed. The wells 
of selected clones were suspended in 300µl of fresh growth media and transferred to fresh 
plates for expansion. 
2.5.2 Identification of prion susceptible cell lines 
To characterise the suitability of cells for inclusion in this study cells were subjected to the SCA 
using serial dilutions of RML and Me7 homogenates from 10-3 down to 10-5. Uninfected cells 
from each line were used as negative controls. Suitable cell lines were those judged to be 
similarly infected by each homogenate according to Elispot spot count. In late 2012 we 
purchased a small stock of 22L prions from the Roslin Institute, Edinburgh, to include in the 
study. The CAD5 cell line was screened against RML, Me7 and 22L at 1:10 serial dilutions of each 
homogenate between 10-4 and 10-7. 
2.5.3 Identification of exclusively propagating clones 
Subclones were infected with two different prion strains, RML and 22L. The selectivity score (SS) 
is defined as the proportion of spots generated by RML infection compared to the number of 
spots from both 22L and RML:  
    𝑆𝑆 =
𝑅𝑀𝐿𝑠𝑝𝑜𝑡𝑠
𝑅𝑀𝐿𝑠𝑝𝑜𝑡𝑠+22𝐿𝑠𝑝𝑜𝑡𝑠
 
After examining pilot data we found it was necessary to further rank hit subclones based on the 
degree to which the preferred strain was propagated over the non-preferred strain. We 
therefore calculated the fold difference (FD) as the ratio of spots from preferred strain to spots 
from the non-preferred strain. 
𝐹𝐷 =  
𝑃𝑟𝑒𝑓𝑒𝑟𝑟𝑒𝑑 𝑠𝑡𝑟𝑎𝑖𝑛 𝑠𝑝𝑜𝑡𝑠
𝑁𝑜𝑛 − 𝑝𝑟𝑒𝑓𝑒𝑟𝑟𝑒𝑑 𝑠𝑡𝑟𝑎𝑖𝑛 𝑠𝑝𝑜𝑡𝑠
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CHAPTER 3 RESULTS 
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3.1 Investigating the role of cellular cholesterol in prion propagation 
3.1.1 Rationale 
The prion protein incorporates into lipid-rich detergent resistant domains in the cell membrane 
(‘lipid rafts’) by virtue of its GPI-anchor. Lipid raft association affects the function of mature PrPC 
(Lewis and Hooper, 2011) and influences intracellular trafficking of the prion protein (Morris et 
al., 2006). Lipid rafts containing PrP are cholesterol rich and are required for cell surface 
localisation of PrP (Gilch et al., 2005). Controversy exists as to whether lipid rafts facilitate or 
limit prion replication and has prompted investigations into how different raft components 
interact with PrP.  
Early work by Albert Taraboulos and colleagues demonstrated that inhibition of cholesterol 
synthesis impaired prion propagation (Taraboulos et al., 1995). Similarly in several studies 
treatment with statins, which inhibit cholesterol synthesis, increased lifespan of prion infected 
mice but did so without any apparent changes in levels of cholesterol or PrPSc (Mok et al., 2006, 
Kempster et al., 2007, Haviv et al., 2008). In cell free models of prion conversion such as Protein 
Misfolding Cyclic Amplification (PMCA) lipids are required as a co-factor for prion conversion; 
synthetic lipids have been used for minimal component PMCA and lipids may form a 
compartment which increases proximity of PrPC and PrPSc during prion conversion (NR et al., 
2007, Wang et al., 2010). Interestingly depletion of glypican-1, which promotes association of 
PrPC with lipid rafts, has been shown to reduce prion propagation (Hooper, 2011). Lipid rafts are 
disputed as a site for prion conversion, with other studies suggesting that acidic organelles such 
as lysosomes may be the site of prion replication (Borchelt et al., 1992, Marijanovic et al., 2009, 
Yim et al., 2015). A recent review (Hannaoui et al., 2014) addressed evidence for cholesterol as 
a co-factor for prion conversion but did little to investigate contradictory findings. 
Work in the group of Chiara Zurzolo shows that lipid raft association stabilises PrP (Sarnataro et 
al., 2004), which may limit prion replication. Similarly in a cell free model Baron and Caughey 
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demonstrated that prion replication is limited by linking PrPC to raft-like liposomes by a GPI 
anchor (Baron and Caughey, 2003). It is possible that lipid raft components other than 
cholesterol influence prion replication. Indeed Naslavsky et al have demonstrated that the rate 
of prion replication is inversely proportional to the sphingomyelin content of cultured prion-
infected neuroblastoma cells (Naslavsky et al, 1999). In light of the work of Prinz et al, which 
showed that oligodendrocytes are resistant prion infection (Prinz et al, 2004), it is likely that 
sphingomyelin limits prion replication. 
The aim of this project was to investigate the effect of depletion of Hmgcr, Dhcr24, Npc1 and 
Npc2; and subsequent changes in cholesterol, on prion propagation. In this chapter I will present 
evidence that cholesterol limits prion replication in cells. We employed a gene silencing 
approach to inhibit both cholesterol synthesis and trafficking, and show here that reducing 
available cholesterol in cells increases prion replication in vitro. 
3.1.2 Perturbing cellular cholesterol synthesis increases prion replication 
Previously chronic prion infection has been shown to induce expression of cholesterogenic 
genes in cells (Bach et al., 2009). However, we observed no difference in total cellular cholesterol 
between S7 and iS7 in the Amplex Red cholesterol assay (Figure 3.1 D). Notably in the work of 
Bach et al, chronic prion infection increased expression of Srebp2, a transcriptional activator of 
Hmgcr. Hmgcr encodes 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), the rate limiting 
step of cholesterol synthesis. We reasoned that as HMGCR acts early in the cholesterol synthesis 
pathway production of intermediate molecules would also be affected by increased HMGCR 
activity. In an attempt to avoid perturbation of intermediate molecules in cholesterol synthesis 
we elected to also investigate the effects of perturbing 3β-hydroxysteroid-Δ24 reductase, which 
catalyses the final step in cholesterol synthesis and is encoded by Dhcr24.  
The Scrapie Cell Assay (SCA) is a method for detecting infectious prion titres in cultured cells 
(Klohn et al., 2003). Prion infected cells are passaged over multiple splits before quantifying the 
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number of cells containing PrPSc by Elispot (see Methods 2.2.1). Gene silencing of both Dhcr24 
and Hmgcr led to an increase in PrPSc-positive cells in both the SCA and in chronically prion 
infected cells (Figure 3.1 A, B). A similar increase in PrPSc-positive cells was seen regardless of 
which gene was silenced, suggesting reduction of cholesterol rather than an unexpected effect 
of either gene was responsible for increased prion replication. Silencing of both Dhcr24 and 
Hmgcr by siRNA was recapitulated in CAD5 cells and was associated with a significant increase 
in PrPSc-positive cells in the SCA (Figure 3.1 C). Multiple siRNAs were tested for each gene; the 
relative change in PrPSc-positive cells for S7 and CAD5 cells are summarised in Table 3.1. 
Despite testing multiple commercial antibodies per target it was not possible to gauge the level 
of Dhcr24 or Hmgcr protein due to poor antibody specificity. Similarly we discovered late in the 
project that our cDNA preparation and qPCR protocols, from which we had been quantifying 
siRNA effects on mRNA levels, were prone to contamination and so we elected to gauge siRNA 
effect by cholesterol phenotype.  Silencing of Dhcr24 reduced cholesterol in cells as measured 
by Amplex Red assay (Figure 3.1 E). Furthermore, silencing Hmgcr reduced filipin labelling in 
cells compared to controls (Figure 3.1 F). As silencing Dhcr24 can lead to accumulation of 
desmosterol (Waterham et al., 2001, Zerenturk et al., 2013), and filipin is a semi-promiscuous 
label which can stain sterols other than cholesterol, this method was not employed to visualise 
cholesterol in cells where Dhcr24 was silenced. 
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Figure 3.1 Silencing Dhcr24 and Hmgcr increases prion propagation Dhcr24 and Hmgcr were 
transiently silenced in cells by transfection with siRNA. S7 (A) and CAD5 (C) cells were infected 
with 10-5 RML prion brain homogenate in cell culture media 3 days after transfection and 
passaged 3 times in the SCA. Chronically RML-infected iS7 cells were seeded for Elispot 3 days 
post-transfection (B). The proportion of PrPSc-positive cells on Elispot assay was normalised to 
percentage of control cells transfected with non-silencing siRNA. Total cholesterol in samples of 
S7 and iS7 cells was determined using the Amplex Red assay and normalised to total S7 
cholesterol (D). E Dhcr24 was transiently knocked down in S7 cells by siRNA transfect. After 3 
days growth total cholesterol levels were determined by Amplex Red assay and normalised to S7 
cells transfected with non-silencing siRNA. F Hmgcr was transiently silenced in S7 cells by siRNA 
transfection. After 3 days growth cells were fixed with PFA, permeabilised with digitonin and 
labelled with filipin. Multiple siRNAs (outlined in Table 3.1) were tested against non-silencing 
control siRNA. Significant difference to control was calculated using Student’s t-test, * p<0.01  
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Lovastatin inhibits the activity of HMGCR and so inhibits cholesterol synthesis. Treating iS7 cells 
with lovastatin was toxic at concentrations above 300nM as measured using the CellTitre Glo 
ATP assay (Promega). Below this concentration there was a non-significant trend towards 
increased PrPSc positive cells following lovastatin treatment (Figure 3.2 A). This result contradicts 
the findings of Taraboulos et al (1995) who reported increased PrPSc in ScN2a cells following 
treatment with lovastatin. Crucially, Taraboulos et al treated cells with lovastatin in reduced fat 
medium and supplemented cells with mevalonate to provide a substrate for non-steroidal 
pathways in the absence of HMGCR activity. However, as mevalonate is produced by HMGCR-
mediated reduction of 3-hydroxy-3-methylglutaryl-CoA this would likely not alter cholesterol 
levels in cells.  
Incubation of S7 cells with methyl-β cyclodextrin (MβCD), a cholesterol sequestering agent, dose 
dependently reduced total cholesterol measured in the Amplex Red assay (Figure 3.2 B).  
Chronically prion infected iS7 cells treated with MβCD exhibited a trend towards increased PrPSc 
positive cells in chronically prion-infected iS7 cells. The number of PrPSc positive cells declined 
sharply at concentrations of MβCD of 100uM and above, although toxicity was not detected in 
the CellTitre Glo assay below 1mM MβCD (Figure 3.2 C). Treatment with sub-toxic 
concentrations of MβCD did not alter levels of PrPC compared to vehicle-treated controls (Figure 
3.2 D). 
Our results demonstrate that perturbing cholesterol synthesis by gene silencing decreases 
cellular cholesterol and increases prion propagation. Treatment with small molecules to reduce 
cellular cholesterol did not significantly increase prion replication and proved toxic at higher 
doses. It is possible that significant increases prion replication were limited in our system by drug 
toxicity occurring before cholesterol levels had been sufficiently reduced.  
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Table 3.1 Silencing Dhcr24 and Hmgcr increases prion propagation in S7 and CAD5 cells. The 
number of PrPSc-positive cells on Elispot assay was normalised to fold change compared to 
control cells for the scrapie cell assay (SCA). Significant differences to control were calculated 
using Student’s t-test (p value). SD –   standard deviation. The siRNA sequences are given in 
Methods Table 2.2. 
S7 
Gene 
Target 
siRNA SCA 
Fold Change SD p value 
Dhcr24 
1 0.88 0.30 0.066 
2 1.83 0.26 1.118x10-27 
3 1.42 0.28 1.407x10-9 
4 1.39 0.27 2.71x10-4 
5 1.38 0.30 6.72x10-3 
6 0.94 0.37 0.480 
7 0.98 0.21 0.785 
8 0.88 0.21 0.120 
9 0.90 0.20 0.726 
10 0.83 0.18 0.022 
11 1.74 0.38 2.44x10-4 
12 1.63 0.42 8.09x10-5 
Hmgcr 
1 1.01 0.21 0.964 
2 1.44 0.18 4.429x10-5 
3 1.34 0.14 0.003 
4 1.18 0.20 0.054 
5 1.45 0.19 0.003 
6 1.29 0.29 0.209 
7 1.06 0.11 0.058 
8 0.79 0.11 0.048 
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CAD5 
Gene 
Target 
siRNA SCA 
Fold Change SD p value 
Dhcr24 
1 1.37 0.23 0.002 
2 0.87 0.18 0.198 
3 1.11 0.23 0.263 
4 1.63 0.08 1.263x10-8 
Hmgcr 
1 1.29 0.30 0.009 
2 1.50 0.14 1.918x10-6 
3 1.08 0.22 0.405 
4 1.00 0.22 0.959 
5 1.18 0.20 0.006 
6 1.05 0.16 0.349 
7 1.47 0.20 1.814x10-8 
8 1.18 0.10 6.403x10-4 
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3.1.3 Increased precursor availability does not increase cellular cholesterol 
We reasoned that increased prion propagation following perturbation of cholesterol synthesis 
may be reversed by increasing cellular cholesterol. Due to difficulties in overexpressing genes in 
our cell lines we sought other methods to increase cholesterol levels in cells. Squalene is 
produced by combination of two Farnesyl diphosphate molecules and is a precursor to 
cholesterol which has been shown to have some protective effects (Gabas-Rivera et al., 2014). 
Crucially squalene is produced after the action of HMGCR, the rate limiting step of cholesterol 
biosynthesis. We considered whether supplementing cell media with squalene could drive 
cholesterol synthesis in cultured cells. Adding 10% squalene to cell media impaired S7 cell 
growth, and Amplex Red assay of cells treated with squalene at concentrations below this level 
did not show a significant change in cholesterol levels relative to untreated control cells (Figure 
3.2 E). 
3.1.4 Depletion of lipoproteins in growth serum disrupts S7 cell membranes 
As the use of small molecules to reduce cholesterol did not cause significant changes in prion 
propagation at sub-toxic doses we sought out alternate methods to deplete cholesterol in cells 
without gene silencing. Reduction of exogenous lipids is frequently used over short incubations 
to reduce cellular cholesterol (Hao et al., 2001, Cheng et al., 2006, Malnar et al., 2012). As the 
SCA requires 3 weeks to complete we investigated how prolonged depletion of lipids in serum 
affected cell viability. Lipoprotein-deficient serum (LDS, Sigma) was used to completely replace 
the 10% fetal bovine serum (FBS) typically used in production of S7 cell culture medium. S7 cells 
were grown in chamber slides in medium containing either FBS or LDS for 3 days after which 
they were fixed, permeabilised and PrP labelled with ICSM18 antibody. Whilst cells cultured with 
FBS exhibited brightly labelled continuous membrane PrP the membranes of cells cultured with 
LDS displayed patchy and weakly labelled PrP (Figure 3.2 F). Incubation with LDS also reduced 
total cell numbers, suggesting toxicity or arrested cell growth. Due to the severity of PrP 
disruption and potential toxic effect LDS was not used for further experimentation. 
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Figure 3.2 Treatment with small molecules which alter cholesterol levels does not significantly 
alter prion propagation A Chronically prion infected iS7 cells were treated with lovastatin for 3 
days and seeded for Elispot. The number of PrPSc-positive cells was normalised to control cells 
treated with DMSO (blue line). Lovastatin toxicity was assessed as percentage viability of control 
cells and determined by the CellTitre Glo assay (Promega, red line). B Treatment of cells with 
methyl-β cyclodextrin (MβCD) for 24 hours significantly reduced cholesterol in the Amplex Red 
assay compared to untreated control cells. * p<0.01, Student’s t-test. C Chronically prion infected 
iS7 cells were treated with MβCD for 3 days and seeded for elispot. The number of PrPSc-positive 
cells was normalised to untreated control cells (blue line), MβCD toxicity was determined by the 
CellTitre Glo assay (Promega, red line). D Uninfected S7 cells were treated with MβCD as above 
and lysed in RIPA buffer. Cell lysates were run on SDS-PAGE and membranes probed for PrP 
(ICSM18, top blot) and Actin (bottom blot). E The cell culture medium of uninfected S7 cells was 
supplemented with squalene and cells grown for 3 days. Total cellular cholesterol was 
determined relative to untreated control cells using the Amplex Red cholesterol assay. F S7 cells 
were incubated for 3 days with Optimem containing either 10% fetal bovine serum (FBS) or 
lipoprotein-deficient serum (LDS). Cells were fixed with 4% PFA for 20 minutes, permeabilised 
with 0.04% Triton X-100 for 10 minutes and PrP labelled with ICSM18 (green). (Figure on next 
page) 
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3.1.5 Optimisation of filipin labelling 
Filipin III is a sterol binding protein which is fluorescent under ultraviolet excitation. Filipin 
optimisation was performed in untransfected S7 cells and first required optimisation of fixation 
conditions. Cells were fixed with 4% PFA for either 10 or 20 minutes followed by 
permeabilisation with either Triton-X 100 (TX100) or digitonin and then labelled with varying 
concentrations of filipin. Treatment with ice cold acetone for 30 seconds was used to strip 
neutral lipids from fixed cells and so provide a negative control for optimisation. At 20 minutes 
PFA fixation filipin was found to produce auto-fluorescence regardless of the labelling 
concentration used. Furthermore, permeabilising cells with TX100 disrupted cell membranes 
and produced bright filipin artefacts. Digitonin permeabilisation left membranes relatively 
undisrupted and was more effective with increased concentration (Figure 3.3 A). As expected 
increasing filipin concentration increased intensity of labelling. Whilst previous studies have 
used 5µg/ml filipin to label cholesterol we found that a 10 minute fix with 4% PFA, followed by 
5 minutes permeabilisation with 100µg/ml digitonin and labelling with 20µg/ml filipin in PBS 
gave the best mix of label intensity and contrast on cell membranes (Figure 3.3 B). Filipin 
labelling under these conditions was selective for neutral lipids as demonstrated by loss of signal 
following 30 seconds acetone treatment (Figure 3.3 C). To better reveal intracellular cholesterol 
fixed cells were instead permeabilised for 10 minutes with 50µg/ml digitonin prior to labelling 
with 20µg/ml filipin in PBS. These conditions were considered optimal and taken forward for the 
remaining images shown in this study. Notably we did not observe a phenotypic difference 
between S7 and chronically prion infected iS7 cells by filipin labelling (Figure 3.3 D).  
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Figure 3.3 Optimisation of filipin labelling A 10ug/ml filipin labelling of S7 cells fixed with 10’ 
4% PFA and permeabilised with increasing digitonin concentrations for 5’ or 10’. B Comparison 
of 10ug/ml and 20ug/ml filipin labelling of S7 cells following digitonin permeabilisation.  C Fixed 
and permeabilised S7 cells were labelled with filipin following 30s treatment with PBS or ice cold 
acetone to strip neutral lipids. D Filipin labelling of S7 cells and chronically prion infected iS7 cells 
in the presence or absence of acetone treatment. (Figure on next page) 
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3.1.6 Silencing Niemann-Pick type C genes impairs cholesterol trafficking 
Niemann-Pick type C is a fatal neurodegenerative lipid storage disorder associated with 
mutations in both Npc1 and Npc2 genes (Blom et al., 2003, Sturley et al., 2004). Loss of function 
of either Npc1 or Npc2 has been widely reported to lead to accumulation of cholesterol in 
lysosomes (Verot et al., 2007, Karten et al., 2009, Vance, 2010, Deffieu and Pfeffer, 2011). Here 
gene silencing was used to recapitulate loss of Npc1 and Npc2 function in our cell models to 
examine the effects of impaired cholesterol trafficking on prion replication. 
3.1.6 (a) Gene silencing of Npc1 and Npc2 exerts unexpected opposing effects on prion replication 
Given Npc1 and Npc2 act sequentially to export cholesterol from lysosomes, and cholesterol is 
thought to be involved in prion replication, it was expected that gene silencing of Npc1 and Npc2 
would exert similar effects on prion replication. As previously reported silencing of Npc1 in S7 
cells decreased the number of PrPSc-positive cells in the SCA (Gilch et al., 2009). Unexpectedly 
silencing Npc2 increased the number of PrPSc-positive cells almost two-fold (Figure 3.4 A). Both 
phenotypes were confirmed across 3 independent experiments containing 12 technical repeats 
each (p<0.01). Similarly silencing Npc1 in chronically infected iS7 cells decreased PrPSc-positive 
cells, but silencing Npc2 did not produce a significant effect compared to non-silencing control 
(Figure 3.4 B). Gene silencing with siRNA was also performed in CAD5 cells. Silencing Npc2 
increased the number of PrPSc positive cells; however an increase in PrPSc positive cells was also 
seen following Npc1 silencing (Figure 3.4 C). As with Hmgcr and Dhcr24 Multiple siRNAs were 
tested for Npc1 and Npc2; the relative change in PrPSc-positive cells for S7 and CAD5 are 
summarised in Table 3.2. 
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Figure 3.4 Silencing Npc1 and Npc2 alters prion propagation Npc1 and Npc2 were transiently 
silenced in cells by transfection with siRNA. S7 (A) and CAD5 (B) cells were infected with 10-5 RML 
prion brain homogenate in cell culture media 3 days after transfection and passaged 3 times in 
the SCA. Chronically RML-infected iS7 cells were seeded for Elispot 3 days post-transfection (C). 
The proportion of PrPSc-positive cells on Elispot assay was normalised to percentage of control 
cells transfected with non-silencing siRNA. Significant difference to control was calculated using 
Student’s t-test, * p<0.01 
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Table 3.2 Silencing Npc1 and Npc2 exert opposing effects on prion propagation in S7 and CAD5 
cells. Gene expression was calculated as percentage expression in control cells transfected with 
non-silencing siRNA. PrPSc-positive cells on Elispot assay was normalised to fold change 
compared to control cells for the scrapie cell assay (SCA). Significant differences to control were 
calculated using Student’s t-test (p value). The siRNA sequences are given in Methods Table 2.2. 
S7 
Gene 
Target 
siRNA SCA 
Fold Change SD p value 
Npc1 
1 0.98 0.25 0.510 
2 0.63 0.21 6.023x10-7 
3 0.73 0.21 1.466x10-4 
Npc2 
1 1.91 0.38 5.356x10-29 
2 1.29 0.43 6.938x10-5 
3 1.12 0.35 0.087 
CAD5 
Gene 
Target 
siRNA SCA 
Fold Change SD p value 
 
 
Npc1 
 
 
 
1 1.51 0.32 1.256x10-4 
2 0.95 0.35 0.651 
3 1.01 0.30 0.940 
4 1.22 0.20 0.038 
5 1.53 0.39 2.216x10-4 
6 1.06 0.24 0.553 
Npc2 
 
1 1.45 0.13 6.970x10-5 
2 1.49 0.30 1.886x10-4 
3 1.51 0.21 3.716x10-5 
4 1.40 0.27 0.001 
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3.1.6 (b) Gene silencing of Npc1 and Npc2 causes accumulation of cholesterol in lysosomes 
Npc1 and Npc2 were silenced by transient transfection of siRNA into cells. Multiple siRNAs were 
tested per gene target, with the siRNA giving best gene silencing taken forward for further 
phenotype testing. As with Dhcr24 and Hmgcr despite testing multiple commercial antibodies 
per target it was not possible to gauge the level of Npc1 or Npc2 protein due to poor antibody 
specificity. As with our experiments on cholesterol synthesis we elected to qualify siRNA effect 
by cholesterol phenotype.  
To confirm that cholesterol accumulated in lysosomes of Npc1- and Npc2-silenced cells confocal 
imaging was used. Initially BODIPY-cholesterol was used to mark cholesterol. Although analysis 
using Volocity software did show a slight increase in co-localisation of BODIPY-cholesterol with 
Lamp1-positive vesicles in gene silenced cells (Figure 3.5 A) the probe was found to be sensitive 
to the fixation conditions used and as such an alternate marker of cholesterol was sought. Filipin 
labelling showed clear accumulation of cholesterol in cells where Npc1 and Npc2 were silenced 
(Figure 3.5 B). This suggests that the opposing effects of Npc1 and Npc2 silencing on prion 
propagation in our models are independent of cholesterol as the same cholesterol phenotype is 
observed with loss of function of both genes. 
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Figure 3.5 Silencing Npc1 and Npc2 causes accumulation of cholesterol in lysosomes A Co-
localisation of BODIPY-cholesterol (green) with Lamp1-positive lysosomes (red) in S7 cells 
silenced with siRNA targeting Npc1 and Npc2. Chart shows co-localisation of BODIPY-cholesterol 
and Lamp1 assessed by Pearson’s Correlation Coefficient using Volocity software. * p<0.05, 
mean ± standard deviation of 10 images. B Filipin labelling of S7 cells silenced with siRNA 
targeting Npc1 and Npc2, fixed by 10’ 4% PFA and permeabilised by 10’ 50ug/ml digitonin. 
Representative images shown. 
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3.1.7 Gene silencing of Npc1 but not Npc2 reduces PrPC protein levels 
Following the widely accepted Protein-only hypothesis prion replication cannot occur without 
the availability of PrPC to act as substrate for conversion to PrPSc. Altered trafficking of 
cholesterol may in turn alter trafficking of PrP. Recently work in our lab has uncovered 
extracellular matrix deposits of disease-associated PrP termed PrPd (Marbiah et al., 2014), with 
levels of PrPd being found to correlate with changes in prion infection. Confocal imaging of 
chronically prion infected iS7 cells in which Npc1 had been silenced showed a reduction in both 
membrane PrP and deposited PrPd (Figure 3.6 A). Gene silencing of Npc2 led to a marked 
increase of PrPd in chronically prion infected cells in line with increased PrPSc-positive cells in the 
SCA. Similar imaging of uninfected S7 cells following silencing of Npc1, but not Npc2, revealed a 
decrease in membrane PrPC (Figure 3.6 B). This effect was not seen in CAD5 cells (Figure 3.6 C). 
To confirm this reduction in PrPC was not due to an off-target effect of the siRNA used (siNpc1.2) 
Western blotting was performed with cell lysates following gene silencing with a further five 
siRNAs targeting Npc1. All siRNAs targeting Npc1 tested reduced PrPC compared to control cells 
treated with non-silencing siRNA; however no siRNA targeting Npc2 significantly altered PrPC 
levels (Figure 3.6 D).  Silencing of Npc1 and Npc2 did not decrease PrPC levels in CAD5 cells 
(Figure 3.6 E). 
 
 
 
 
Figure 3.6 Silencing Npc1 reduces expression of PrPC Npc1 and Npc2 were transiently silenced 
in iS7 (A), S7 (B) and CAD5 (C) cells in chamber slides by siRNA transfection; after 3 days growth 
cells were fixed with PFA and permeabilised by 30s treatment with ice-cold acetone and 10 
minutes treatment with 3M GTC before antibody labelling PrP (ICSM18, green) and Lamp1 (red). 
In all cases nuclei were labelled with DAPI (blue). Reduced PrPC following silencing of Npc1 but 
not Npc2 was confirmed by Western blotting in S7 cells (D) but notCAD5 cells (E). The relative 
density of ICSM18 signal was calculated using ImageJ software and normalised to actin signal. 
Representative blots shown. (Figure on next page)  
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3.1.8 Gene silencing of Npc1 decreases lysosomal pH 
The activity of some lysosomal enzymes is dependent on pH, and many such enzymes are more 
active in more acidic environments (Pillay et al., 2002). Lysosomal pH is maintained by the flux 
of ions across the lysosome membrane, particularly the import of H+ ions via an ATP-dependent 
pump (Vandyke, 1993, DiCiccio and Steinberg, 2011). The accumulation of cholesterol or other 
cargo in lysosomes may disrupt ionic flux and so alter lysosomal pH. Intracellular pH changes 
were monitored by live-imaging of cells pre-incubated with Lysosensor Green DND-189 
(‘Lysosensor’, Life Technologies) which accumulates and exhibits increased fluorescence 
intensity in acidic compartments. Silencing Npc1 but not Npc2 increased Lysosensor 
fluorescence compared to control cells indicating decreased pH (Figure 3.7 A). Increased 
Lysosensor fluorescence co-localised with Dextran Texas Red in live cells indicating the acidic 
compartments were lysosomes (Figure 3.7 B). Increased lysosomal acidity may in part account 
for the reduction in PrPC observed following Npc1 gene silencing in S7 cells. That we did not see 
this effect in CAD5 cells suggests reduced PrPC is due to an unknown factor in N2a-S7 cells and 
not a direct result of Npc1 silencing. 
We reasoned that the reduction of PrPC observed following silencing of Npc1 could be due to 
increased degradation of PrPC and so may be reversed by directing PrP trafficking away from 
lysosomes. Rab9 has been shown to function in the transport of mannose-6-phosphate 
receptors and epidermal growth factor receptors (EGFR) from late endosomes to the trans-Golgi 
network (Ng et al., 2012) and reversed the effect of U18666A (which can cause phenotypes 
similar to Npc1 silencing) in decreasing PrPSc (Gilch et al., 2009). S7 cells overexpressing Rab9 
were kindly provided by Lucy Sheytanova. Overexpression of Rab9 in S7 cells did not rescue PrPC 
reduction following Npc1 silencing (Figure 3.7 C). 
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Figure 3.7 Silencing Npc1, but not Npc2, alters lysosomal activity in uninfected cells A Live cell 
imaging with lysosensor green DND-189 in cells silenced with siRNA targeting Npc1 and Npc2. 
Fluorescence indicates acidic compartments. B Co-localisation of lysosensor (green) fluorescence 
with Dextran Texas Red (red) in S7 cells silenced with siRNA targeting Npc1. Cells were incubated 
overnight with 100µg/ml Dextran Texas Red followed by 30 minutes incubation with 100nM 
Lysosensor immediately prior to imaging. C S7 cells stably overexpressing Rab9 or empty pLNCX.2 
vector were transfected with siRNA targeting Npc1 and grown for 3 days. Cell lysates were run 
on SDS-PAGE and membranes probed for PrP (ICSM18, top blot) and Actin (bottom blot).  
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3.1.9 Detection of lipid microdomains in the cell membrane 
Recent work by Chiara Zurzolo and colleagues (Sarnataro et al., 2004) suggests that PrPC is 
stabilised in lipid rafts. Theoretically PrPC could become less stable, and so be more readily 
converted to PrPSc, if lipid rafts are disrupted. We initially sought to observe changes in lipid rafts 
by confocal microscopy using GM1 to mark lipid rafts. Cholera toxin subunit B (CtxB) is a well 
characterised label for GM1 (Vanheyningen, 1976, Jobling et al., 2012) and we employed a pulse-
chase protocol to detect changes in both surface presentation and intracellular trafficking of 
GM1. In chronically infected iS7 cells CtxB co-localised with deposits of disease associated PrPd 
in the extracellular matrix (Figure 3.8 A). S7 cells exhibited very low expression of GM1, with 
occasional cells showing high CtxB labelling, whilst CAD5 cells displayed an intense membrane 
signal when labelled with AlexaFluor-555 conjugated CtxB (Figure 3.8 B). Colocalisation of CtxB 
and PrPd in the extracellular matrix of iS7 cells suggested that prion infection caused 
sequestration of GM1/CtxB into prion deposits, but the scarcity of CtxB-positive iS7 and S7 cells 
prevented further investigation. The intensity of labelling in CAD5 cells precluded further 
investigation as it was not possible to view individual lipid raft domains under the conditions 
tested.   
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Figure 3.8 Basement membrane deposits of PrPd contain GM1 A S7 and iS7 cells were grown in 
chamber slides, pulsed with 5µg/ml CtxB-555 (red) at 12°C for 30 minutes to label GM1 then 
immediately fixed with PFA and permeabilised by 30s treatment with ice-cold acetone and 10 
minutes treatment with 3M GTC to uncover PrPd deposits in the basement membrane of infected 
cells. PrP was labelled with ICSM18 antibody (green) following permeabilisation. B CAD5 cells 
exhibit higher and more uniform GM1 expression than S7. S7 and CAD5 cells were labelled with 
CtxB-555 as above, fixed with PFA and permeabilised with 0.04% Triton X-100. All slides were 
counterstained with DAPI (blue) to label nuclei. Representative images shown. 
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3.1.9 (a) Optimisation of gradient centrifugation to isolate lipid rafts 
As an alternative to confocal microscopy we instead elected to isolate lipid rafts by gradient 
centrifugation in order to investigate alterations in rafts following cholesterol perturbation.  We 
adapted the protocol of Waheed and Jones (2002) to isolate lipid rafts by ultracentrifugation on 
a continuous Optiprep gradient. As our rotor required the use of larger ultracentrifuge tubes 
than those used by Waheed and Jones the final volume of the gradient was doubled to 9ml as 
described in Methods (Section 2.4.6). In all tests the spin speed was kept consistent at 
41000rpm, the maximum available for the SW 41Ti rotor used. At full speed this exerted an 
average acceleration of 207000g down the gradient. As we would be using cultured cells rather 
than tissue we needed to optimise the number of cells prepared per lysate and so compared 
pellets of 1 million, 3 million and 10 million S7 cells. No signal was observed following fractioning 
of 1 million cells but both 3 million and 10 million cells showed good signal in fractions towards 
the top of the gradient on Western blot (Figure 3.9 A). Due to reduced reagent requirements 
and lower background signal pellets of 3 million cells were taken forward for further 
experimentation. As PrP was only observed in a single 1ml fraction using 3 million cells the 
sensitivity of the assay was increased by further dividing fractions 1-4 as described in Methods 
which allowed for observation of smaller movements of PrP through the gradient.  
We reasoned that a 16 hour centrifugation step at over 200000g may compress our gradient 
and lead to PrP only being located in a single fraction. To address this we compared the 16 hour 
spin to shorter 4 and 8 hour spins at the same speed using 5 million cells per pellet.  On short (1 
minute) exposure of membrane to film only the 16 hour spin showed detectable PrP in more 
than one fraction, which was mainly found in the first and second fraction of the gradient (Figure 
3.9 B). Longer (10 minutes) exposure of film showed detectable levels of PrP across the gradient 
for both 16 and 8 hour spins, whilst the 4 hour spin showed separate pools of PrP in the upper 
and lower fractions of the gradient (Figure 3.9 C). The 16 hour spin time was selected for further 
investigation of PrP and lipid rafts. In order to increase resolution down the gradient fractions 
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were collected in smaller volumes which could be pooled to reproduce the initial 9 fractions as 
described in Methods (Section 2.4.6). Gradient centrifugation of CAD5 cells revealed that PrPC 
was primarily located in fractions also containing CtxB-labelled GM1, indicating lipid rafts. 
Conversely Lamp1, which is found in lysosomal membranes (Carlsson and Fukuda, 1989), was 
spread across the upper end of the gradient including PrPC and CtxB-containing fractions (Figure 
3.9 D). 
 
 
 
 
 
 
 
Figure 3.9 Optimisation of lipid raft isolation using Optiprep gradients A Pellets of 106, 3x106 
and 107 S7 cells were lysed on ice in 1ml TNET buffer and run on Optiprep gradients for 16 hours 
as described. 1ml fractions were collected from the top of the gradient and run on SDS-PAGE to 
probe for PrP (ICSM18). Pellets of 3x106 S7 cells were run on Optiprep gradients at 207000g for 
4, 8 and 16 hours. 1ml fractions were collected from the top of the gradient and run on SDS-PAGE 
to probe for PrP (ICSM18); membranes were exposed for 1 minute (B) and 10 minutes (C) to 
determine location of PrPC. D 3x106 CAD5 cells were incubated with 10µg/ml biotinylated CtxB in 
PBS for 45 minutes at 4°C and washed 3 times by pelleting and resuspending in PBS. Labelled 
cells were run on Optiprep gradients as above for 16 hours. 1ml fractions were collected from 
the top of the gradient and run on SDS-PAGE to probe for PrP (ICSM18, top blot) and Lamp1 
(bottom blot marked 98kDa). CtxB was detected by blocking membrane overnight in 5% 
milk/PBST and incubating with Streptavidin-HRP (Sigma, 1:20000 in PBST). Labelling CtxB in this 
way produced a single band at approximately 11kDa per containing fraction. (Figure on next 
page) 
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3.1.9 (b) Impaired cholesterol synthesis and trafficking shifts PrPC from raft fractions to lower 
buoyant densities 
We observed a shift of PrP across the gradients in chronically infected iS7 cells compared to S7 
cells (Figure 3.10 A) which was also seen in comparison of CAD5 and RML prion infected iCAD5 
cells. Labelling CtxB in CAD5 and iCAD5 cells revealed that PrP shifted out of GM1-containing 
fractions in iCAD5 cells (Figure 3.10 B).  
 
Figure 3.10 Prion infection shifts PrP out of lipid raft fractions on Optiprep gradients Pellets of 
3x106 S7/iS7 (A) and CAD5/RML-infected iCAD5 (B) were run on Optiprep gradients as described 
above. Twelve 333µl fractions (i-xii) were collected from the top of the gradients and run on SDS-
PAGE to probe for PrP (ICSM18). As above CtxB labelling of CAD5 fractions was achieved by pre-
incubation of cell pellets with biotinylated CtxB and probing blotted membranes with 
Streptavidin-HRP.  
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Knockdown of Dhcr24 has previously been reported to reduce PrP flotation in low-density 
fractions of sucrose gradients (Crameri et al., 2006). Silencing of both Dhcr24 and Npc2 shifted 
PrPC down Optiprep gradients compared to control cells (Figure 3.11 A). Remarkably this 
phenotype could be reproduced by siRNA knockdown of Dhcr24 and Npc2 in primary neuronal 
cultures (Figure 3.11 B). As with comparison of chronically infected and uninfected cells labelling 
of CtxB in gradients was limited to CAD5 cells. Silencing Dhcr24 shifted PrPC out of CtxB-labelled 
fractions however silencing Npc2 also produced a shift of CtxB down the gradient (Figure 3.11 
C). Gradients were performed a minimum of three times in cultured cells. In primary neurons 
only two repeats were performed due to time constraints and the availability of acceptable and 
viable cell cultures. With one exception, as with silencing Npc2 (see Figure 3.6) we did not 
observe a difference in PrP levels following Dhcr24 silencing (Figure 3.12). In an attempt to 
better characterise gradients samples were subject to a BCA assay, however protein levels were 
found to be so low as to not produce any signal above background using BSA standards 
increasing from 25pg/ml. 
 
 
 
 
 
Figure 3.11 Impaired cholesterol trafficking and synthesis shifts PrP out of raft fractions Pellets 
of 3x106 S7 (A) and CAD5 (C), and 106 primary cortical neurons (B), were prepared from cells 
transiently transfected with siRNA targeting Dhcr24 and Npc2. Lysates were run on Optiprep 
gradients as above for 16 hours and twelve 333µl fractions collected from the top of the gradient. 
Selected fractions were run on SDS-PAGE to probe for PrP (ICSM18). CAD5 cells were pre-
incubated with biotinylated CtxB as described in Methods (2.4.7) to label GM1-containing 
fractions. (Figure on next page) 
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Figure 3.12 Silencing Dhcr24 does not alter PrPC levels in S7 cells Pellets of 1x106 S7 were 
prepared from cells transiently transfected with siRNA targeting Dhcr24, lysed in RIPA buffer and 
run on SDS-PAGE to probe for PrP (ICSM18). Following the first probe membranes were stripped 
and re-probed with anti-actin antibody to control for protein loading. Blots were analysed using 
ImageJ software, relative protein levels are shown in below each lane (RD). Only siRNA Dhcr24.1 
increased PrP levels. This siRNA was earlier removed from other experiments due to a lack of 
effect in the SCA. 
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3.2 Rare variant subclones of CAD5 cells selectively propagate different 
prion strains 
3.2.1 Rationale 
Prion strains are characterised by the proportional ‘pattern’ of glycosylation they exhibit, their 
in vivo incubation time and the lesion profiles and pattern of PrPSc deposition they produce in 
infected tissue (Collinge, 2005). A growing body of evidence suggests that the species barrier 
that limits cross-species transmission of prion disease may in part be due to susceptibility to 
different prion strains (Hagiwara et al., 2013). Prion strains may contain pools of different PrPSc 
conformers (Collinge, 2010). There is growing evidence that prion strains can adapt to different 
host cells (Li et al., 2010) with the implied possibility that only a few conformers are able to 
replicate in a given host and so outgrow their competition. Strains are highly robust and can be 
passaged in vivo multiple times without altering their characteristics.  
Cell culture models have revealed that different cell lines are susceptible to infection by different 
prion strains (Mahal et al., 2007) although all strains are thought to be infectious in vivo. This 
suggests that prion strain susceptibility is a cellular factor and as such may be genetically 
encoded. Furthermore, it stands to reason that if a given set of cellular factors encodes 
susceptibility to a given prion strain and the cell line itself is susceptible to multiple prion strains 
then it may be possible to alter susceptibility to one prion strain but not the other. It is possible 
that differences in cellular susceptibility to different prion strains could help account for the 
different patterns of PrPSc deposition observed in brain tissue. We asked whether it was possible 
to isolate cells which are restricted in susceptibility to a single strain from a less restricted parent 
line. As with the recent work of Marbiah et al (2014) deriving multiple cell lines from the same 
parent line should reduce differences in gene expression unrelated to the phenotypes being 
selected for. I show here that subcloning of the CAD5 cell line, which is susceptible to multiple 
prion strains, will yield rare variant subclones which exclusively propagate a single strain. These 
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rare variants may exhibit a different pattern of gene expression than their cousins, providing a 
‘gene signature’ for strain selection.  
The work of Mahal et al (2007) compared the cell lines PK1, R33, LD9 and CAD5, and the prion 
strains RML, 22L, Me7 and 301C. At the outset of this project we had access to all 4 cell lines (as 
well as the PK1 subclone PK1-11) and prion strains RML and Me7. PK1, R33 and CAD5 are derived 
from mouse neuroblastoma whilst LD9 are derived from mouse fibroblast. The PK1 subclone S7 
used elsewhere in this thesis was judged unsuitable for this project as it had previously been 
subcloned and selected for high RML susceptibility (Marbiah et al., 2014). 
The aim of this project was to isolate rare variant subclones which exclusively propagate a single 
prion strain, and to then investigate cellular factors underlying this strain selection. 
3.2.2 LD9, R33 and PK1-11 cells are unsuitable for identifying rare variant cell subclones 
To isolate rare cognate cell clones which exclusively propagate a single prion strain we checked 
whether any of the parent cell lines were susceptible to multiple prion strains. Serial dilutions of 
RML and Me7 infected brain homogenate were used to perform an SCA for LD9, PK1-11 and R33 
cells. PK1-11 cells were found to be highly susceptible to RML but not Me7 rendering them 
unsuitable for the project (Figure 3.13 A). Both LD9 and R33 were found to propagate RML and 
Me7 prions similarly; however the low susceptibility to either homogenate rendered R33 
unsuitable for use (Figure 3.13 B). Whilst LD9 cells were a strong candidate based on this data 
(Figure 3.13 C), they were highly adherent and not suitable for high-throughput screening of 
subclones using automated equipment.  
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Figure 3.13 The responses of PK1-11, R33 and LD9 cells to prion infection are unsuitable for 
rare variant subclone isolation PK1-11, R33 and LD9 cells were infected with RML (blue) and 
Me7 (red) homogenate in concentrations increasing from 10-5 to 10-3 dilutions of homogenate in 
growth media. Control cells were uninfected. After reaching confluence post-3rd passage cells 
were seeded for elispot at a density of 20000 cells per well and PrPSc levels were assessed. A PK1-
11 cells are highly susceptible to RML prion infection and respond proportionally to changing 
homogenate concentration, but are resistant to the Me7 prion strain. B R33 cells are not 
susceptible to both RML and Me7 prion strains. C LD9 cells respond similarly to both RML and 
Me7 prion strains. However, the highly adherent nature of these cells made them unsuitable for 
high throughput screening. In all cases 12 wells of a 96 well plate were challenged with each 
dilution of homogenate. Bars show mean spot count ± standard deviation for each dilution, 
control = growth media with no homogenate. (Figure on next page) 
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3.2.3 CAD5 cells are highly susceptible to RML and 22L prion strains 
To test whether the catecholaminergic cell line CAD5 was suitable for use in our search for 
exclusively propagating cognate cell clones a trial SCA was performed with serial dilutions of 
each homogenate. Three prion strains, RML, 22L and Me7, were tested at concentrations 
between 10-4 and 10-7 dilutions of brain homogenate. Cells were found to be highly susceptible 
to two strains, RML and 22L, consistent with previous reports (Mahal et al., 2007). The cells were 
less susceptible to the third strain, Me7, and yielded spot numbers higher than background only 
at the highest concentration of homogenate used (Figure 3.14). Due to their high susceptibility 
to RML and 22L we selected CAD5 cells for a proof of concept experiment. 
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Figure 3.14 CAD5 cells are highly susceptible to multiple prion strains and are suitable for rare 
variant subclone isolation Elispots of 20000 cells per well were collected at post-2nd (white bars) 
and post-3rd (black bars) splits of the SCA for CAD5 cells infected with serial dilutions of RML, 22L 
and Me7. At higher concentrations of homogenate both RML and 22L led to saturation of the 
plate reader used above 3000 spots (dotted line) so no absolute spot count was recorded. CAD5 
cells were relatively unsusceptible to Me7, returning a mean of only 216 spots at post-3rd elispot 
for the highest homogenate concentration tested. Bars show mean spot count ± standard 
deviation for each dilution. 
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3.2.4 CAD5 subcloning yields rare variant cells which are exclusively susceptible to distinct 
prion strains 
Following the identification of CAD5 as a viable cell line, 288 subclones were infected with a 10-
5 dilution of RML and 22L. Across the subclone population the mean response to both RML and 
22L infection was similar (Figure 3.15 A). A selectivity score (SS) was calculated as described in 
methods, with the mean SS being 0.485 ± 0.186 (3sf ± standard deviation, Figure 3.15 B). In this 
initial experiment we identified 13 rare variants, a ‘hit rate’ of ~4.5%. Of the 13 clones identified, 
9 selectively propagated RML whilst 4 preferred 22L (outlined in Table 3.3). Rare variants such 
as these may eventually be used to identify potential gene signatures for strain selectivity once 
sufficient subclones have been isolated. Whilst validating our pilot data it became clear that cell 
susceptibility to prion infection would be lost over multiple passages consistent with previous 
findings. We therefore elected to optimise a high throughput cryopreservation method in order 
to retain the early characteristics of our subclones with restricted susceptibility to prion strains.  
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Figure 3.15 CAD5 subcloning yields rare variant subclones which exclusively propagate a single 
prion strain A The mean and standard deviation of RML (687±327) and 22L (812±538) elispot 
spot count for a pilot run of 288 subclones infected with 10-5 RML or 22L homogenate in the SCA. 
Each subclone was tested twice against each prion strain. B The selectivity score was calculated 
as the ratio of RML spots to total spots for each subclone and assumed a Gaussian distribution, 
giving a mean of 0.485 across the experiment with a standard deviation of 0.186. 13/288 
subclones gave scores more than 2 standard deviations from the mean and were classed as 
variants. Of these rare variants 9 displayed a preference for RML and 4 a preference for 22L. 
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Table 3.3 Rare variant CAD5 subclones exclusively propagate distinct prion strains. RML- and 
22L-preferring subclones were selected in addition to non-preferring subclones, listed according 
to experimental plate layout. RML, 22L = number of spots on elispot for each prion strain. SS = 
selectivity score, the ratio of RML spots to total spots for each subclone. FD = fold preference for 
the preferred prion strain (preferred/non-preferred).  
 
RML Preferring  
Subclone RML  22L  SS RML FD 
1B8 131 11 0.923 11.9 
1E9 1018 70 0.936 14.5 
1F11 992 89 0.918 11.1 
2A4 1080 99 0.916 10.9 
2D12 460 50 0.902 9.2 
2F6 493 75 0.868 6.6 
3A6 694 65 0.914 10.7 
3C11 477 45 0.914 10.6 
3G8 425 31 0.932 13.7 
22L Preferring  
Subclone RML  22L  SS 22L FD 
1A2 30 763 0.038 25.4 
1G1 9 165 0.052 25.4 
2A9 13 283 0.044 18.3 
2G4 20 305 0.062 21.8 
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3.2.5 Expansion of CAD5 subcloning assay for increased throughput 
Whilst validating our pilot data it became clear that cell susceptibility to prion infection would 
be lost over time consistent with previous findings. We therefore elected to optimise a high 
throughput cryopreservation method in order to retain the early characteristics of our subclones 
with restricted susceptibility to prion strains. 
Although 96-well plate freezing allowed increased throughput we were still limited by the 
number of Elispot assays which could be performed simultaneously. A further 480 subclones 
were screened against both RML and 22L prion strains, testing 2 biological repeats per 
homogenate and freezing an additional copy of each subclone to preserve the lowest passage 
cell iteration possible. Elispot data was again collected at post-3rd passage giving spots counts of 
1431±850 for RML and 1091±923 for 22L (mean ± standard deviation). Selectivity scores were 
calculated with mean 0.565 and standard deviation 0.169 across the population (Figure 3.16); 
subclones were selected if the selectivity score lay more than 2 standard deviations from the 
mean. To increase stringency of selection a threshold of at least 500 spots for the preferred 
homogenate was required to class a subclone as responsive. This yielded 3 RML-responsive and 
2 22L-responsive subclones, an additional 4 neutral subclones were selected to serve as controls 
(Table 3.4). 
Upon resurrection only 5 of the selected subclones were viable (3 RML preferring, 1 22L 
preferring, 1 neutral). These subclones were expanded and again challenged with 10-5 RML and 
22L, testing 8 repeat wells per subclone. Selectivity scores were again calculated for each 
subclone and compared to selectivity scores obtained in the initial test (Figure 3.16 C). Non-
selective preference and preference for RML were maintained, whilst the 22L-preferring 
subclone lost selectivity and became non-preferring. Our findings here demonstrate that whilst 
improved cryopreservation increases the chances of procuring rare variant subclones further 
work is required to ensure these clones remain viable as candidates for our investigation. 
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Figure 3.16 Selective susceptibility to RML is preserved in subclones A An increased cohort of 
480 subclones was infected with 10-5 RML or 22L in the SCA. The new cohort maintained the high 
mean spot count and standard deviation observed in the pilot run. RML spot count (1431±850) 
trended to be higher than 22L spot count (1091±923). B Selectivity scores across the cohort 
assumed a Gaussian distribution with mean 0.565 and standard deviation 0.169. 3 RML 
preferring, 2 22L preferring and 4 non-preferring subclones were selected for further work. C 
Upon resurrection selected subclones were expanded (8 wells/test). 3 RML preferring, 1 22L 
preferring and 1 non-preferring subclone survived resurrection and were retested with 10-5 RML 
and 22L in the SCA (8 wells/test). RML preference (red points/lines) and neutral preference (grey 
points/line) was maintained whilst 22L preference (blue points/line) was lost as selectivity score 
moved above 0.5.  
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Table 3.4 Subclones selected for further analysis following increased throughput subcloning. RML- and 22L-preferring subclones were selected in addition to non-
preferring subclones, listed according to experimental plate layout. RML1, RML2, 22L1, 22L1 = number of spots on elispot for each technical repeat, means and 
standard deviations given as RML/22L Mean and SD. SS = selectivity score, the ratio of RML spots to total spots for each subclone. FD = fold preference for the 
preferred prion strain (preferred/non-preferred), FD for 22L used for non-preferring subclones. 
RML Preferring 
Subclone RML 1 RML 2 
RML 
Mean RML SD 22L 1 22L 2 
22L 
Mean 22L SD SS 
RML 
FD 
A1G 3152 2514 2833 451 127 475 301 246 0.904 9.4 
C10F 2186 2653 2420 330 239 137 188 72 0.928 12.9 
C11F 1858 975 1417 624 161 124 143 26 0.909 9.9 
             
22L Preferring  
Subclone RML 1 RML 2 
RML 
Mean RML SD 22L 1 22L 2 
22L 
Mean 22L SD SS 
22L 
FD 
A5G 819 938 879 84 3237 2856 3047 269 0.224 3.5 
D4F 235 327 281 65 706 1937 1322 870 0.175 4.7 
             
Non Preferring  
Subclone RML 1 RML 2 
RML 
Mean RML SD 22L 1 22L 2 
22L 
Mean 22L SD SS 
22L 
FD 
A4F 1725 1956 1841 163 1792 1800 1796 6 0.506 1.0 
C4C 2397 2137 2267 184 2220 2195 2208 18 0.507 1.0 
C2E 2159 1820 1990 240 1807 1905 1856 69 0.517 1.1 
D8A 1846 1701 1774 103 1860 1898 1879 27 0.486 0.9 
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CHAPTER 4 DISCUSSION 
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4.1 Impairment of the cholesterol metabolism facilitates prion 
propagation 
This work provides evidence that perturbation of cholesterol facilitates prion propagation in 
cells. Inhibition of cholesterol synthesis by transient knockdown of Dhcr24 and Hmgcr both 
reduced cellular cholesterol levels and increased prion propagation. Similarly, the sequestration 
of cholesterol in lysosomes by silencing of Npc2 increased prion replication. A thorough study of 
cell- and gene-dependent effects following transcriptional silencing of Npc1 and Npc2, two 
genes with a role in cholesterol trafficking, provides a rational to understand conflicting data of 
this work with previous studies. Previous work by Gilch et al (2009) demonstrated that silencing 
of Npc1 decreased the level of PrPSc in N2a cells, a result that could be replicated in this work, 
but is in conflict to the increase in prion replication following Npc2 knockdown. As Npc1 and 
Npc2 work in tandem to export cholesterol from lysosomes, and silencing of either gene causes 
accumulation of cholesterol, effects on the corresponding rates of prion replication were 
expected to follow the same trend. Further characterisation of Npc1-silencing in S7 cells, a 
subclone of N2a, revealed that PrPC levels were depleted alongside an increase in lysosome 
acidity in Npc1-, but not in Npc2-silenced cells. Reasoning that decreased PrPC would limit prion 
replication (S et al., 1996, Daude et al., 2003), we tested silencing of Npc1 in CAD5 cells. Whilst 
PrPC levels were indistinguishable from control levels, knockdown of Npc1 and Npc2 cells in 
CAD5 cells significantly increased the rates of prion replication in both cases. This suggests that 
the decrease in prion propagation following loss-of-Npc1 function is cholesterol-independent 
and caused by an unidentified cellular factor. In summary, lysosomal sequestration of 
cholesterol by transcriptional silencing of Npc1 and Npc2 is associated with increased prion 
replication when PrPC expression levels remain unaltered, a conclusion that is in agreement with 
an increase of prion replication rates at limiting cholesterol levels following perturbation of 
cholesterol biosynthesis. 
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To better understand how both the reduction and sequestration of cholesterol may explain an 
increase in prion propagation, the distribution of PrPC between raft and non-raft membrane 
domains was investigated. Gradient ultracentrifugation revealed a shift of PrPC from raft to 
lower buoyant density membrane fractions following silencing of Dhcr24 and Npc2. In 
agreement with this result, sucrose gradient density centrifugation of lysates from Dhcr24+/- 
mouse brain homogenates showed a shift of PrPC from raft to lower buoyant density fractions 
when compared to wild-type mice (Abad-Rodriguez et al., 2004, Crameri et al., 2006). Lipid raft 
association is known to stabilise PrPC (Sarnataro et al., 2004) and we asked whether lipid raft 
disruption by cholesterol depletion predisposed PrPC to conversion into PrPSc.  
Altered cholesterol metabolism has implications for other neurodegenerative diseases such as 
Alzheimer’s disease. By studying the role of cholesterol in PrP processing and prion replication 
it may be possible to better understand pathology in other diseases. Notably, PrP levels have 
been shown to regulate beta secretase cleavage of APP (Parkin et al., 2007), an effect which may 
in part be mediated by PrP binding to lipid rafts. Similarly, work by Bart de Strooper and 
colleagues have shown differential activity of gamma secretase dependent on lipid raft 
association (Nesic et al., 2012) suggesting that further study of cholesterol in neurodegenerative 
disease could help us understand how APP processing is affected by lipids. Indeed, Dhcr24 
expression is known to correlate with protection against Alzheimer’s disease (Crameri et al., 
2006). Our data here suggests that expression of Dhcr24 (and so production of cholesterol) may 
limit prion replication which could have implications for the formation of amyloid plaques in 
other disease. Interestingly the interaction of PrP with lipids has been suggested as a potential 
mechanism for neurotoxicity in Alzheimer’s disease. In a recent paper Watt et al suggested that 
PrP-dependent uptake of zinc is disrupted by binding of Aβ oligomers to PrP (Watt et al, 2014). 
Disruption of lipid rafts and PrP by Aβ binding may contribute to toxic effects in Alzheimer’s 
disease. 
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4.1.1 Reduction in the availability of cholesterol promotes prion replication 
Our findings directly contradict reports that cholesterol depletion impairs prion propagation and 
indicates that cholesterol is not a co-factor for prion replication. Instead our data suggests that 
reduced cellular cholesterol facilitates prion propagation. We perturbed cholesterol synthesis 
by silencing of Hmgcr and Dhcr24 which are key genes in the Mevalonate pathway. Silencing 
Hmgcr almost completely depleted membrane cholesterol and increased prion replication. 
Similarly silencing Dhcr24 reduced total cellular cholesterol by ~40% and increased prion 
replication. We elected to silence Dhcr24 as it acts late in the synthesis of cholesterol and so 
would not be expected to disrupt production of other intermediate molecules. Indeed silencing 
of Dhcr24 in cells has previously been shown decrease cholesterol alongside accumulation of 
desmosterol, whilst complete knockout of Dhcr24 in mice was lethal (Wechsler et al., 2003, 
Mirza et al., 2006). Contrary to our reasons for targeting Dhcr24 Hmgcr acts early in the 
Mevalonate pathway and is required for production of many intermediate and bioactive 
molecules. Hmgcr is however the rate limiting enzyme in cholesterol synthesis and is also the 
target of the statin family of cholesterol lowering drugs. We did not observe toxic or growth 
effects when silencing either Hmgcr or Dhcr24, possibly due to cells retaining sufficient 
cholesterol to maintain normal functions over the 3 day silencing period. We did not attempt to 
overexpress Dhcr24 or Hmgcr in order to increase cholesterol production. As Hmgcr is rate 
limiting we did not expect to see a significant increase in cholesterol production with Dhcr24 
overexpression. Similarly, cholesterol synthesis is tightly regulated (Pfrieger, 2003, Yeganeh et 
al., 2014) and it is possible that negative feedback would prevent increased cholesterol 
production when overexpressing Hmgcr. Finally work in our group and others have shown 
difficulty in stably overexpressing genes in S7 and CAD5 cell models. We were concerned that 
the rigorous infection and selection protocols required for gene expression in our cell lines 
would impair prion propagation and so sought other methods to increase cholesterol in cells. 
122 
 
Subsequent experiments performed after completion of my research indicate that knockdown 
of Dhcr24 with certain siRNAs, particularly Dhcr24.2, may increase cell proliferation in 
chronically infected iS7 cells. Throughout my experimentation phase we were careful to monitor 
cell proliferation, reasoning that altered proliferation could impact prion propagation, and did 
not observe changes in cell growth when silencing Dhcr24. In repetition experiments an increase 
in the rate of prion propagation after transcriptional silencing of Dhcr24 as described in the 
results section could not be confirmed by an independent researcher. In these experiments the 
rate of prion replication was normalised to the cell number. As a decrease in cholesterol levels 
resulted in an increase of cell proliferation, an effect that had previously not been noticed, no 
significant changes in prion replication were observed under these conditions. Further 
experiments will be undertaken to clarify these findings. Critically cholesterol depletion by 
MβCD has been shown to enhance myoblast proliferation, putatively by increased expression of 
the cell cycle regulator p53 (Portilho et al., 2012). Conversely increased cholesterol has been 
shown to rescue cell proliferation defects in the CNS (Cunningham et al., 2015) and it is possible 
that cholesterol exerts different effects on cell proliferation in different tissues.  
We also investigated impaired cholesterol trafficking alongside cholesterol synthesis. As 
referenced throughout this thesis, in 2009 Gilch et al demonstrated that inducing cholesterol 
accumulation in lysosomes of prion infected N2a cells by silencing Npc1 or with the small 
inhibitor U18666A impaired prion replication. In line with the work of Taraboulos et al 
(Taraboulos et al, 1995) this was interpreted as limiting the availability of cholesterol as a co-
factor for prion replication. Whilst U18666A does cause cholesterol accumulation in lysosomes 
it is not fully characterised and may cause other off target effects (Cenedella, 2009, Browman 
and Zurzolo, 2013). Our data confirms that silencing Npc1 in the N2a subclone S7 causes 
accumulation of cholesterol in lysosomes and reduces the number of PrPSc-positive cells in our 
assays. However when silencing Npc1 in CAD5 cells, which are from a distinct lineage to N2a 
cells, we observed increased prion replication. Furthermore silencing Npc2, which produced an 
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identical phenotype of lysosomal cholesterol accumulation as silencing of Npc1, increased prion 
replication in both S7 and CAD5 cells. We found a decrease in PrPC levels in S7 cells following 
Npc1 silencing and reasoned this may explain reduced PrPSc in these cells (see section 4.1.3 
below). When interpreted in the context of our findings that impaired cholesterol synthesis 
promotes prion replication our work on Npc1 and Npc2 suggests that accumulation of 
cholesterol may facilitate prion replication through a similar mechanism. With both reduced 
synthesis and impaired trafficking of cholesterol there would be expected to be a net reduction 
in available cholesterol in cells which may disrupt lipid rafts. If lipid rafts stabilise PrPC as 
reported in the work of Sarnataro et al (2004) then a loss of lipid rafts may destabilise PrPC 
allowing for more ready conversion to PrPSc. 
Over the course of our study we utilised several methods of tracking and quantifying cholesterol 
in cells. We initially experimented with tracking cholesterol by confocal imaging with the aim of 
eventually tracking cholesterol in live cells. In 2008 work in Elina Ikonen’s lab characterised 
boron dipyrromethene difluoride cholesterol (BODIPY-cholesterol) as a marker of cholesterol 
trafficking in live cells (Holtta-Vuori et al., 2008). Using BODIPY-cholesterol we were able to track 
cholesterol intracellularly but did not observe membrane labelling in fixed or live cells. 
Furthermore, as BODIPY-cholesterol is an analogue of cholesterol we were unable to use it to 
quantify cholesterol levels in cells. Filipin III is a cholesterol binding toxin which is isolated from 
bacteria and fluoresces when excited with ultraviolet (UV) light (Schroeder et al., 1971). Michael 
Duchen (UCL Department of Physiology) kindly allowed us access to his UV capable confocal 
microscope but due to the logistics of preparing samples for imaging we were unable to examine 
filipin labelling in live cells. Additionally, due to the wide emission spectrum of filipin (Norman 
et al., 1972) we were unable to label samples with antibodies alongside filipin to determine the 
location of different organelles relative to cholesterol. We were able to determine relative 
cholesterol levels both intracellularly and in cell membranes using filipin labelling in fixed cells. 
Using a combination of BODIPY-cholesterol and filipin staining experiments we were able to 
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determine that our silencing of Npc1 and Npc2 produced the expected phenotype of cholesterol 
accumulation in S7 cells. To quantify cholesterol levels in cells we used the commercial Amplex 
Red cholesterol assay (Life Technologies). This assay allowed us to determine total cholesterol 
in cells and with optimisation may allow for differentiation between esterified and free 
cholesterol. Modifying the assay in this way would be useful in investigating the effects such as 
Acat1 and Lipa which produce enzymes to esterify cholesterol and hydrolyse cholesterol esters 
respectively. 
Although the role of cholesterol in prion propagation remains controversial in published 
literature it is possible that more recent studies interpret data in light of early work by Albert 
Taraboulos and colleagues which showed that lovastatin inhibits prion replication (Taraboulos 
et al., 1995). In our hands lovastatin proved toxic to cells above 300nM and concordantly 
reduced PrPSc levels in chronically prion infected iS7 cells. However at sub-toxic concentrations 
there was a trend for lovastatin treatment to increase prion replication, an effect which was 
mimicked by treatment with the cholesterol sequestering agent methyl β-cyclodextrin. A key 
experimental difference between our work and that of Taraboulos et al is that mevalonate was 
used to supplement treated cells in the latter study in order to provide for non-steroidal 
pathways downstream of HMGCR activity. We opted not to supplement cells with mevalonate 
as this still feeds into cholesterol synthesis (Goldstein and Brown, 1990) and would be expected 
to nullify the action of lovastatin.  
Furthermore the reduction in PrPSc observed by Taraboulos et al was primarily seen when 
lovastatin treatment was combined with use of reduced-fat serum in cell media, an effect 
reversed by supplementing media with cholesterol (Taraboulos et al., 1995). Depletion of 
exogenous cholesterol and other lipids by ‘starving’ cells with depleted media is a common 
research technique and has previously been shown to reduce cell membrane integrity (Grundner 
and Jokhadar, 2014) and increase membrane protein shedding (Murai et al., 2011). In our hands 
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complete replacement of fetal bovine serum with lipoprotein-deficient serum proved toxic, 
severely disrupted cell membranes and altered distribution of PrPC. Indeed, work by Gilch et al 
(2005) has shown that cholesterol is required for cell surface localisation of PrPC and so depletion 
of lipids including cholesterol would be expected to replicate this effect. Whilst Taraboulos and 
colleagues successfully demonstrated reduction in PrPSc by depletion of exogenous lipids our 
data suggests that this may be due to impaired cell cycling and availability of PrPC.  
Methyl β-cyclodextrin (MβCD) sequesters cholesterol from cell membranes and has previously 
been shown to cure prion infection in cells (Prior et al., 2007). Prior et al demonstrated that 
500µM MβCD reduced PrPSc levels by almost 60% in N2a cells chronically infected with 22L 
prions. Whilst we did not test a 500µM dose of MβCD we observed reduced PrPSc at doses of 
100µM and 300µM which was associated with approximately 25% reduction in cellular 
cholesterol. Treatment with 1mM MβCD was toxic as measured by the CellGlo Titre assay but 
did not reduce levels of PrPC or actin on Western blot. We elected to treat cells for 3 days after 
allowing cells to adhere whilst Prior et al passaged cells in the presence of MβCD for 1 week. 
Cholesterol can also be increased in cells by incubating MβCD with cholesterol prior to treating 
cells (Christian et al., 1997). In this system MβCD-cholesterol acts as a cholesterol donor 
however Prior et al observed that this further reduced PrPSc when used in combination with 
MβCD. This suggests that the effect of MβCD in reducing PrPSc may occur independently of 
cholesterol, and furthermore the fact that addition of cholesterol further reduced PrPSc levels 
may help support our hypothesis that cholesterol limits prion replication. As MβCD has an 
antiprion effect we did not attempt to increase cellular cholesterol using MβCD-cholesterol in 
our study. 
In an attempt to increase cholesterol production in cells I supplemented culture medium with 
squalene. Squalene is a cholesterol precursor which is generated after Farnesyl diphosphate in 
the Mevalonate pathway (Nurenberg and Volmer, 2012), and so does not feed into non-
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cholesterogenic pathways. Despite increasing squalene dose to 10% (v/v) in medium, a 
concentration which was toxic for cells, no sub-toxic squalene dose increased cellular 
cholesterol as measured by the Amplex Red cholesterol assay (Life Technologies). It is possible 
that squalene was not taken up into cells and so was not used as a substrate for cholesterol 
synthesis. Due to difficulties in overexpressing gene candidate coding sequences in N2a 
subclones and CAD5 cells we were unable to test the effect of overexpression of Dhcr24 or 
Hmgcr on prion propagation. Expression of cholesterogenic genes is tightly regulated (Yeganeh 
et al., 2014) and it is possible that had gene overexpression been successful effects may have 
been limited by negative feedback from transcription factors. 
4.1.2 Altered cholesterol metabolism reduces association of PrPC with lipid rafts 
As cholesterol is a key component of lipid rafts in the cell membrane we reasoned that disrupted 
cholesterol metabolism could impair association of PrP with lipid rafts. As lipid rafts have been 
shown to stabilise PrPC (Sarnataro et al., 2004) we hypothesised that perturbed cholesterol 
synthesis and trafficking would shift PrPC out of rafts leading to reduced stability and increased 
availability for conversion to PrPSc. We initially attempted to visualise lipid rafts by confocal 
microscopy. Whilst we tested several antibodies against known lipid raft components including 
flotillin-1, flotilin-2 and CD81 few worked at the high level of specificity required for fluorescence 
imaging. Subsequently we used Cholera toxin subunit B (CtxB) conjugated to the red Alexa Fluor 
555 fluorophore (Sigma) which binds tightly to the sphingolipid GM1 (Sugimoto et al., 2001). 
Imaging of CtxB in S7 cells was not possible due to low numbers of cells which could be labelled. 
Conversely, CAD5 cells were intensely labelled by CtxB to the point where we were unable to 
discriminate between different membrane regions by microscopy. The discrepancy in CtxB 
labelling between S7 and CAD5 cells suggests that only a few S7 cells present GM1 ganglioside 
on the cell membrane. Whilst this does not rule out lipid raft formation in S7 cells it suggests 
that these may be formed from different sphingolipid components. Research by other groups 
indicates that lipid rafts in N2a cells also contain sphingomyelin and that the rate of prion 
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replication is inversely proportional to the level of sphingomyelin present in rafts (Naslavsky et 
al., 1999). 
As an alternative to microscopy we opted to isolate rafts by gradient centrifugation. A key 
biological determinant of lipid rafts is their resistance to detergents at low temperatures and 
several protocols exist for raft isolation on gradients (Naslavsky et al., 1997, Crameri et al., 2006, 
Persaud-Sawin et al., 2009). We opted to adapt a protocol using Optiprep which had previously 
been used to isolate lipid rafts in COS-7 cells and demonstrated raft sensitivity to methyl-β 
cyclodextrin treatment (Waheed and Jones, 2002). The protocol was found to be sensitive to 
both the amount of lysate loaded onto gradients and the length of time for which the samples 
were centrifuged. Our optimised protocol used lysate from 5 million cells, which gave good 
signal on Western blot without accumulating insoluble material in the top of the gradient, and 
a 16 hour spin which showed good definition of raft and non-raft fractions on the gradient. By 
pre-incubating CAD5 cells with biotinylated CtxB prior to lysis we were able to determine the 
location of GM1, and by extension lipid rafts, on gradients. Discussion of the data has since 
indicated that the concentration of TX-100 used may have been too high and partially solubilised 
rafts. This may account for spreading of PrP across fractions, and would require further 
optimisation in subsequent experiments if this study were to be continued. 
As previously reported PrPC was found in lipid raft fractions in gradients of uninfected cells whilst 
PrP from lysates of prion infected cells migrated across the gradient and was found in more 
soluble fractions as well as rafts (Lewis et al., 2012).  We observed a shift in PrP in gradients run 
using lysates of both RML infected S7 and CAD5 cells. Remarkably this shift of PrP out of raft 
fractions could be partially replicated by silencing of Dhcr24 and Npc2 in both S7 and CAD5 cell 
lines as well as primary neuronal cultures. In 2006 Crameri et al showed a loss of PrPC buoyancy 
in raft fractions in lysates of mice heterozygous for expression of Dhcr24 whilst overexpression 
of Dhcr24 in SH-SY5Y cells increased PrPC buoyancy in these fractions. Similarly Naslavsky et al 
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demonstrated that PrPC buoyancy in low density fractions could by blocked by treating samples 
with Saponin suggesting cholesterol is required for this phenotype (1997). We did not attempt 
gradient centrifugation of cells treated with MβCD or lovastatin as our data from chronically 
infected cells suggested that these treatments were not as clean a model of cholesterol 
reduction as gene silencing. In their comparison of the different effects of cyclodextrins on prion 
infection Prior et al showed that PrPSc but not PrPC is shifted to soluble fractions of sucrose 
gradients of lysates of β-cyclodextrin treated cells (2007). β-cyclodextrin reduced cholesterol by 
a similar amount to MβCD in this study and also caused a slight shift in GM1 towards soluble 
fractions, indicating that cholesterol may be partly responsible for detergent resistance in lipid 
rafts. Our data supports evidence that PrP-containing lipid rafts are cholesterol-rich and can be 
disrupted by silencing key genes involved in cholesterol metabolism. As silencing Dhcr24 and 
Npc2 led to increased prion propagation in cells we reasoned that a change in cellular 
environment could make PrPC more available for conversion to PrPSc, potentially as a result of 
reduced stability after exiting lipid rafts. 
Taken together our findings indicate that cholesterol limits prion replication and that this may 
be due to the requirement of cholesterol in targeting PrPC to lipid rafts. Our data directly 
contradicts previous reports from the Prusiner lab that inhibition of cholesterol synthesis 
impairs prion replication (Taraboulos et al., 1995). Recently the role of cholesterol in prion 
disease was reviewed by Hannaoui et al, approaching the subject from a viewpoint that 
cholesterol facilitates prion replication (2014). Several key findings are discussed including 
disruption of PrP-containing lipid rafts following cholesterol depletion and links between 
cholesterol and Aβ formation in Alzheimer’s disease; however it becomes apparent that in 
several cases the role of cholesterol may have been overlooked in favour of accepting the 
findings in the early work of Taraboulos et al. Indeed in cases cholesterol remained unchanged 
by treatment (Mok et al., 2006, Kempster et al., 2007, Haviv et al., 2008), and in some cases links 
to disruption of cholesterol metabolism were speculative (Mange et al., 2000). Whilst for the 
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main part these were elegant, expertly performed experiments it seems possible that results 
may have been misinterpreted in light of early data presented by the Nobel Prize winning Stan 
Prusiner. 
4.1.3 Npc1 knockdown in S7 cells reduced PrPC levels 
Niemann-Pick type C disease is characterised by lysosomal accumulation of cholesterol (Sturley 
et al., 2004) and can be caused by loss of function in Npc1 or Npc2 (Vance, 2006). Because of 
the similarities in the loss of function phenotype for Npc1 and Npc2 we initially assumed 
silencing either gene would produce a similar effect on prion replication. Silencing Npc1 has 
previously been reported to impair prion propagation in N2a (Gilch et al., 2009) an effect 
thought to be mediated by enhanced degradation of PrPSc. In agreement with Gilch et al we 
observed a reduction in PrPSc-positive cells when silencing Npc1 in SCA of uninfected and 
chronically prion infected S7 cells which are an N2a subclone (Klohn et al., 2003). Our data shows 
that silencing of Npc1 also reduced PrPC in S7 cells. In line with the protein-only hypothesis the 
availability of PrPC limits prion replication. Silencing Npc1 did not reduce PrPC in CAD5 cells and 
silencing Npc2 did not alter PrPC levels in either S7 or CAD5 cells. As silencing of Npc1 and Npc2 
produces an identical phenotype, and silencing Npc1 in CAD5 increased the number of PrPSc-
positive cells, our data indicates that the previously reported effects of Npc1 silencing on prion 
replication may be independent of cholesterol. Furthermore, as reduced PrPC was limited to 
silencing Npc1 in S7 but not CAD5 cells it appears likely that this is the result of an S7-specific 
intermediate factor and not necessarily a result of Npc1 loss of function. 
We considered whether silencing of Npc1 altered lysosomal function and so increased 
degradation of PrPC. Experiments using Lysosensor green DMD-189 revealed that lysosomes in 
Npc1-silenced cells were more acidic than lysosomes in control cells transfected with non-
silencing siRNA. As lysosomal enzymes are more active in more acidic environments (Pillay et 
al., 2002) we hypothesised that PrPC and other proteins were degraded more efficiently in 
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lysosomes of Npc1-silenced cells. Since evidence suggests PrPC is normally recycled through 
sorting endosomes rather than being trafficked to lysosomes we also considered whether PrPC 
was being increasingly diverted to lysosomes in Npc1-silenced cells. Although we did not 
investigate PrP turnover further in these cells it may be possible to confirm whether reduced 
PrPC is a result of increased degradation or impaired protein synthesis using a cycloheximide 
assay to block protein synthesis (Obrig et al., 1971). If silencing Npc1 impairs synthesis alone 
then PrPC levels would be expected to decrease evenly between silenced and control cells. 
Conversely, increased degradation would become apparent by a more rapid decrease in Npc1-
silenced cells compared to controls. Given we observed changes in lysosomes in line with 
increased lysosomal activity increased degradation rather than perturbed synthesis seems the 
more likely candidate for the reduction in PrPC seen when silencing Npc1. 
In an attempt to reverse PrPC depletion following Npc1 ablation in S7 cells we overexpressed 
Rab9. Rab9 is a GTPase which functions in the transport of cargo away from the 
endosomal/lysosomal system (Ng et al., 2012). In the work of Gilch et al expression of Rab9 
partially reversed the observed reduction in PrPSc following treatment with U18666A (Gilch et 
al, 2009). We reasoned that Npc1 knockdown may alter intracellular trafficking, and perhaps 
increase the likelihood of lysosomal degradation of, PrPC. As such overexpression of Rab9 was 
an attempt to remove PrPC from the lysosomal compartment prior to degradation. Although 
Rab9 overexpression did not alter PrPC levels this does not mean that other regulators of 
endocytosis would be similarly unable to prevent reduction of PrPC. Given that Arf6 has been 
shown to restore cholesterol trafficking in Npc1-/- cells it may be interesting to examine whether 
Arf6 expression similarly rescues PrPC levels following Npc1 knockdown. Indeed, expression of 
constitutively active Arf6 (with the point mutation Q67L) altered PrPC trafficking and suggested 
a role for Arf6 in clathrin-independent endocytosis of PrP (Kang et al., 2009). 
4.1.4 Future work  
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Due to time restraints work not covered here will investigate the ability of PrPC from different 
gradient fractions to covert to PrPSc. Protein Misfolding Cyclic Amplification (PMCA) is an in vitro 
model of prion replication whereby sequential rounds of sonication and incubation are used to 
amplify a prion seed in samples containing PrPC (Saborio et al., 2001). Recently it has been 
demonstrated that PrPC isolated from high buoyancy fractions in sucrose gradients is not a 
substrate for PMCA (Mays et al., 2014) suggesting that raft association protects against prion 
conversion. Initial experiments indicate that PrPC obtained from gradient fractions is a substrate 
for PMCA conversion, albeit with a very low yield in part due to low levels of protein in each 
fraction. We attempted to increase protein concentration by loading higher cell numbers onto 
gradients; however this resulted in a large pool of insoluble material which occupied the top 1ml 
of the gradient and did not shift following gene knockdown. To overcome low fraction protein 
levels we are attempting a two-round PMCA protocol whereby fractions are first used to amplify 
an RML seed with limited sonication followed by a seeding the product of this round into mouse 
brain homogenate for an increased sonication step. 
Alongside PMCA it may be possible to determine the stability of PrP in gradients biochemically. 
In work not shown here we attempted to clone a tetracysteine binding motif into PrPC to allow 
for biarsenical labelling similar to the work of Taguchi et al (2008). Although theoretical we 
reasoned that a cryptic motif would become available for binding during denaturation, allowing 
us to determine PrP stability as a function of denaturation time or concentration of denaturing 
agent. Existing protocols have employed denaturation with urea (Kim et al., 2009) and guanidine 
(Peretz et al., 2001) to determine the stability of various proteins. We generated multiple 
tetracysteine-containing PrP clones but were unable to stably express our constructs, halting 
work on this experiment in favour of more promising leads. As an alternative we are now 
considering antibody labelling of PrP. As our antibody of choice, ICSM18, recognises a linear 
epitope (Klohn et al., 2012) it may prove difficult to determine the level of protein unfolding due 
to denaturation. The ability of misfolded PrP to resist degradation by PK is a key biochemical 
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characteristic of PrPSc (Oesch et al., 1985). It may be possible to determine the stability of PrPC 
in different gradient fractions by testing resistance to a low concentration of PK over increasing 
digestion times. 
Following the early work of Taraboulos et al there have been multiple attempts to thwart prion 
disease using cholesterol-lowering drugs. Notably Simvastatin, an analogue of lovastatin already 
used in patients to protect against hyperlipidaemia (Thanh et al., 2012), has been shown to 
increase the lifespan of prion infected mice (Mok et al., 2006, Kempster et al., 2007, Haviv et al., 
2008). However these studies do not show differences in levels of PrPSc and in some cases do 
not show a reduction in CNS cholesterol (Mok et al., 2006, Kempster et al., 2007). Interestingly 
in one study demonstrating a neuroprotective effect of Simvastatin a parallel increase in PrPSc 
was observed (Haviv et al., 2008) although cholesterol levels were not changed. This suggests 
that antagonism of the mevalonate pathway reduces prion toxicity independent of cholesterol. 
As our data shows reduced cholesterol following Dhcr24 knockdown increasing prion replication 
in cell culture it will be important to see how this translates to effects in vivo. Work by Mirza et 
al (2006) has shown that Dhcr24-null mice are not viable and so we intend to knockdown Dhcr24 
by RNAi in wild type mice. We have outsourced production of AAV constructs to Vector Core 
(Penn State University) containing novel short hairpin RNA targeting Dhcr24. While the final 
experimental planning is ongoing the overall intention is to silence Dhcr24 in the brains of young 
prion infected mice and to observe differences in lifespan and prion deposition. 
 Prion infection is known to stimulate cholesterol biosynthesis (Bach et al., 2009) although we 
did not observe a difference in cholesterol levels between uninfected and infected S7 cells. 
Having recently discussed these findings with Ina Vorberg, who directed the studies of Bach and 
Gilch, we considered how prion infection may disrupt cholesterol metabolism to account for 
these changes. Prion infection may partially disrupt lipid raft structure and cholesterol 
metabolism (Kumar et al., 2008, Cui et al., 2014) which could feedback to the cholesterol 
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synthesis pathway. Controversially, if cholesterol limits prion replication as suggested by our 
data, then increased cholesterol production following prion infection may be seen as an 
adaptive response aimed at preventing the spread of PrPSc. Although there is no strict evidence 
for either theory it seems more likely that cells respond to perturbed cholesterol homeostasis 
rather than initiate an innate protective mechanism against prion disease. 
4.1.5 Implications for prion disease 
The site of conversion of PrPC to PrPSc remains elusive. Both endosomes/lysosomes (Borchelt et 
al., 1992, Marijanovic et al., 2009) and membrane domains (Kaneko et al., 1997, Sunyach et al., 
2003) have been suggested as potential conversion sites. In a 2002 review of the role of lipid 
rafts in disease Jacques Fantini proposed that raft association increased PrPC and PrPSc proximity 
and so facilitates prion propagation (Fantini et al., 2002). Conversely, Roger Morris has 
suggested that conversion to PK-resistant PrP occurs after PrPC leaves lipid rafts to be 
internalised and trafficked intracellularly (Morris et al., 2006). There is growing evidence for this 
theory: GPI-linked PrPC in model rafts resists conversion to PrPSc in cell free models (Baron et al., 
2002), depletion of sphingomyelin from rafts increases prion replication (Naslavsky et al., 1999) 
and PrPSc formation is reduced when formation of the multivesicular body is impaired (Yim et 
al., 2015). Our data suggests that cholesterol depletion shifts PrPC out of rafts and that this is 
associated with increased prion replication. 
Given that cholesterol lowering drugs prolong survival time in prion infected mice, and early 
research suggested that inhibition of cholesterol synthesis prevents accumulation of PrPSc, 
reducing cellular cholesterol presents an attractive target for treatment of prion disease. 
However our data contradicts these findings and demonstrates that impaired cholesterol 
synthesis and trafficking increases prion replication. If PrPSc is the toxic agent in prion disease 
then its increased replication would be expected to hasten patient mortality. So as not to diddle 
future patients out of a potentially effective treatment further research is required to assess the 
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role of cholesterol in prion replication. Our data suggests that cholesterol reduction disrupts 
binding of PrPC to lipid rafts which promotes prion replication by an unknown mechanism. 
Naslavsky et al have previously demonstrated that sphingomyelin reduction by treatment with 
fumonisin B1 (FB1) increased levels of PrPSc in chronically infected cells (Naslavsky et al., 1999). 
The theory that sphingomyelin impairs prion replication is supported by evidence that 
oligodendrocytes, which express high levels of sphingomyelin for myelin sheath production, are 
resistant to prion infection (Prinz et al., 2004). In a more recent study FB1 treatment reduced 
PrPSc in RML-infected GT1 cells, with the authors suggesting differences in the models used 
between the studies accounted for this contrast (Agostini et al., 2013). Notably Naslavsky et al 
reported that PrPC association with raft fractions was not affected by FB1 treatment, and as 
previously reported by Gilch et al it is the cholesterol component of lipid rafts required for 
binding of PrPC (2005). Given that PrP has a sphingolipid binding domain analogous to the V3 
loop of HIV envelope protein (Mahfoud et al., 2002) and lipid raft association is involved in 
stabilising PrPC (Sarnataro et al., 2004) a potential protective role for both cholesterol and 
sphingolipid components of lipid rafts emerges. Theoretically sequestration of PrPC into rafts by 
cholesterol-GPI anchor interaction allows for sphingomyelin binding to the V3-like loop 
stabilising PrPC and limiting prion replication. Depletion of cholesterol prevents sequestration of 
PrPC into rafts, preventing sphingomyelin binding and so rendering PrPC unstable enough for 
prion replication. Similarly when sphingomyelin is depleted PrPC still binds to cholesterol in rafts 
but is not stabilised by binding at the V3-like loop allowing for prion replication. This model is 
represented in Figure 4.1. In this model prion replication would occur in non-cholesterol or 
sphingolipid depleted systems when PrPC is trafficked out of rafts for endosomal recycling. The 
site of prion conversion remains controversial and this model would not discriminate between 
conversion in non-raft membrane areas or along the endocytotic pathway.  
There are several experiments which could be performed to test this model. Previously 
Naslavsky et al have shown that treatment of prion infected cells with PDMP, a glycosphingolipid 
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inhibitor which increased sphingomyelin levels, reduced PrPSc in cells (Naslavsky et al, 1999). It 
may be possible to block sphingolipid binding to PrPC, either using a small inhibitor or by 
expressing a truncated PrP mutant which lacks the V3-like loop region. It may be interesting to 
see whether the V3-like loop is required for conversion or is exclusively involved in sphingolipid 
binding and protein stability. We would be able to rapidly screen truncation mutants of PrP 
expressed in cells using the SCA, and indeed this technique has recently been used in the MRC 
Prion Unit to perform an alanine mutagenesis screen of critical regions in PrP for prion 
replication (Savroop Bhamra & Parmjit Jat, unpublished observations). We could also investigate 
PrP stability using a denaturing assay such as those suggested above to investigate the stability 
of PrPC in different gradient fractions. It is possible that alterations in the V3-like loop could 
decrease protein stability by preventing sphingomyelin binding, however if an introduced 
mutation sufficiently alters folding of PrP then stability may be increased. As such other assays 
to determine protein structure, perhaps x-ray crystallography, may be required downstream to 
investigate this model.  
 Potentially the effects of sphingomyelin and cholesterol in limiting prion replication may be 
synergistic. As such treatments which reduce levels of both cholesterol and sphingomyelin 
should further increase prion replication compared to treatment which only reduces one of the 
two lipids. As both cholesterol and sphingomyelin are key components of the cell membrane a 
reduction in both may be toxic to cells. Early in this project we considered whether stable 
knockdown of genes such as Dhcr24 would be counterproductive, with the most efficiently 
silenced cells effectively selecting themselves out of experiments due to impaired viability. It 
may therefore be necessary to titrate treatments to balance lipid reduction and cell viability, 
and a combination of gene silencing and treatment with small inhibitors may prove useful.   
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4.2 Cellular factors influence susceptibility to prion strains 
Cultured cell lines display different patterns of susceptibility to different prion strains. Similarly, 
different prion strains elicit different patterns of neuronal lesions and PrPSc deposition in vivo. It 
stands to reason that differences between different cell types affect permissiveness to different 
prion strains leading to these effects. Given the suggestion that prion strains exist as a pool of 
conformer quasispecies and the discovery that prion strains can adapt to differences in brain 
and cultured cells (Li et al., 2010) we considered whether cellular factors affected the ability of 
prion strains to propagate. We reasoned that isolation of closely related cells which propagate 
different prion strains would allow for examination of these cellular factors with minimal 
masking from other cell phenotypes.   
Whilst this project’s primary aim of isolating subclones which exclusively propagate a single 
prion strain was met we did not attempt the second objective of determining which cellular 
factors regulate susceptibility to different prion strains. This was primarily due to the time 
required to build a substantial cohort of rare variant subclones which was limited by the time 
required to passage subclones through the SCA. Even with high throughput screening on the 
MRC Prion Unit robots, which allow for up to 20 96-well plates to be processed in a single run, 
the number of tests required for each subclone limited us to a maximum of 480 subclones per 
run.   
4.2.1 CAD5 subcloning yields rare variant cells which exclusively propagate a single prion 
strain 
The catecholaminergic neuronal cell line CAD5 is susceptible to both RML and 22L prion strains 
and gives similar levels of propagation of each strain as assessed by Elispot following the SCA. 
By subcloning CAD5 cells we were able to isolate rare variant cells which exclusively propagate 
either RML or 22L. Whilst only a small cohort of these rare variants was isolated our data suggest 
that exclusive propagation of RML was maintained over several passages. 
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In agreement with previous reports we found CAD5 cells to be slightly more susceptible to RML 
than 22L or Me7 (Mahal et al., 2007). This was especially apparent at higher concentrations of 
homogenate where RML infection led to the number of PrPSc-positive CAD5 cells saturating the 
detector used in our assays. We excluded Me7 from further experimentation as the number of 
PrPSc-positive cells obtained in our assays was far less than the spot counts recorded for 22L or 
RML. At the 10-5 dilution of homogenate used for our cohorts there was a notable increase in 
PrPSc-positive cells following RML infection compared to infection with 22L in our initial 
experiments, however this difference was not seen in our screening assays. Data from both 
subclone runs showed similar responses across the entire population to RML and 22L, with high 
standard deviations for both homogenates indicating wide variation in the number of PrPSc-
positive cells recorded. By transforming spot count data into the ratio of RML spots compared 
to total spots (selectivity score, SS) we were able to account for preferences in cells whilst also 
accounting for the expectation that different subclones would be more or less susceptible to 
prion infection by any strain. When the number of subclones was plotted as a function of SS the 
data assumed a normal distribution with a mean close to 0.5 suggesting our subclone 
populations were not biased in susceptibility towards either RML or 22L. 
Despite the distribution of SS being seemingly without skew we isolated greater numbers of 
RML-exclusive than 22L-exclusive subclones. Additionally our pilot data suggests that exclusive 
susceptibility to RML is more stable than exclusive susceptibility to 22L. We attempted to reduce 
bias in this study by infecting cells with the same dilution of each homogenate but in light of the 
work of Mahal et al a more tailored approach may be more appropriate for future work. Mahal 
et al characterised response indexes (RI) for the prion strains tested, equivalent to the reciprocal 
of the homogenate concentration required to produce 300 spots on an elispot of 20000 cells 
(Mahal et al., 2007). It may be better to titre our infections to the RI obtained for our 
homogenates in our cells. We did produce a crude attempt at this comparing infection of CAD5 
cells with RML and 22L over 4 log dilutions of homogenate but only considered this as evidence 
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of susceptibility to each strain in our experimental plan. Mahal et al showed similar RIs for both 
RML and 22L in CAD5 cells. By comparing concentrations of homogenates which should produce 
equal numbers of PrPSc-positive cells per strain we may be able to reduce bias towards one 
strain. Of course changing the volume of homogenate added to cells may in itself skew results 
as there is the potential for toxic (non-prion) agents such as reactive oxygen species to be 
conferred by brain tissue (Driver et al., 2000). As such samples may need to be buffered to a 
fixed concentration using uninfected mouse brain homogenate as a negative control for prion 
infection studies.  
Both RML and 22L are mouse adapted strains of Scrapie PrPSc and as such may display similar 
adaptations to cell lines. Indeed the work of Mahal et al reveals that four cell lines which 
propagate 22L also propagate RML (2007). Whilst this did not prevent us from isolating 
exclusively propagating rare variant subclones in this study it is possible that a more notable 
difference could be seen in a cell line which demonstrates highly competent replication of one 
strain but a more limited (but still detectable) replication of another. To continue using the work 
of Mahal as an example CAD5 cells recorded a RI ~30-fold greater for 22L than the 301C prion 
strain (2007). For reference Mahal et al recorded only a 2-fold difference in RI between RML and 
22L in favour of RML. Building on further work from this lab it may be possible to isolate 
extremely rare variant subclones which propagate 301C preferably to 22L which may display 
more pronounced differences than those seen between RML- and 22L-preferring subclones. 
4.2.2 Cell lines other than CAD5 were not suitable for subcloning 
Prior to selecting CAD5 as our cell line of choice for this project we tested several other lines. 
For various reasons these cell lines were unsuitable for our experimental design but our work 
with them supports the hypothesis that cellular factors influence susceptibility to different prion 
strains. PK1-11 and R33 cells are both derived from the N2a cell line (Klohn et al., 2003) but 
display different susceptibility to RML prions. Similarly whilst both PK1-11 and LD9 cells are 
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susceptible to RML only LD9 cells were susceptible to Me7 in our initial experiments. We sourced 
22L prions fairly late in the project after ruling out these cell lines and so did not test propagation 
of 22L in R33, LD9 or PK1-11 cells. Previously R33, LD9 and PK1 (of which PK1-11 are a subclone) 
cell lines have been shown to be susceptible to 22L prions although to different extents (Mahal 
et al., 2007).  
We excluded R33 cells on the basis that they are resistant to prion infection by RML and Me7. 
This is unsurprising given that R33 were originally isolated as an RML-resistant subclone of N2a 
cells (Klohn et al., 2003). Subcloning of R33 may prove interesting in the future to identify 
subclones which regain susceptibility to RML. We recently published work similar to this 
whereby prion-resistant PK1 subclones were isolated alongside highly susceptible cells (Marbiah 
et al., 2014). In this study we identified a network of gene expression associated with 
remodelling of the extracellular matrix which also regulated susceptibility to prion infection. In 
this study the gene expression of R33 and other N2a subclones were mapped to 3D transcript 
profiles which revealed that R33 cells were distinct from other subclones used in the study. As 
such it is possible that cellular factors other than those which regulate extracellular matrix 
remodelling are responsible for resistance to prion infection in R33 cells. 
PK1-11 cells were excluded from further experimentation as they were susceptible to RML but 
not Me7. It is possible that PK1-11 may also be susceptible to 22L prions but this was not tested 
here. We reasoned that a cell line which already exclusively propagated one prion strain, but 
not another, provided evidence that strain susceptibility is encoded by cellular factors but was 
not a good model for our intended study. If PK1-11 cells are susceptible to 22L, which is likely 
given that the parent PK1 cell line is susceptible (Mahal et al., 2007), then these cells may be a 
potential model in the future to confirm our CAD5 findings. Not only might we be able to confirm 
if a given set of genes or processes are required for susceptibility to a given strain but the PK1-
11 model may prove more stable than CAD5. Noticeably in out pilot study exclusive susceptibility 
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to 22L was lost over a few passages. If exclusive susceptibility is not stable then we may be 
unable to confirm cellular factors underlying this phenotype. If PK1-11 cells provide a more 
stable model of exclusive susceptibility to 22L than CAD5 they may be a more useful model in 
future work. 
Whilst LD9 cells were susceptible to both RML and Me7 prion strains we did not take them 
forward in this study as they were unsuitable for high throughput screening. We found LD9 cells 
were far more adherent than N2a subclones and so unsuitable for resuspension on our in house 
robot. Automated processing was of particular importance to our experimental design as we 
thought exclusively susceptible subclones would be very rare and so require screening of large 
subclone cohorts. Prior to obtaining 22L prions LD9 presented the best option for our subcloning 
project. LD9 cells could be passaged in the SCA by hand and as such we attempted to optimise 
automated passaging of LD9 cells on our robot. We considered whether the bore of the pipette 
tips used on the robot combined with the pressure applied was insufficient to aspirate cells from 
the plate surface. We tested several different types and sizes of pipette tips, along with different 
resuspension volumes, but were unable to easily resuspend LD9 in growth media. Our standard 
culture conditions to maintain LD9 in petri dishes requires trypsinisation to passage cells. We 
attempted to optimise trypsinisation for the 96 well plate format and were able to successfully 
passage LD9 cells on the robot in this way. However we reasoned that as trypsin can cause the 
internalisation of surface proteins such as PrP (Caughey et al., 1988) doing so may interfere with 
prion propagation as the site of conversion of PrPC to PrPSc is currently unknown. By this point 
in the study we had characterised the response of CAD5 cells to RML and 22L and so LD9 cells 
were dropped in favour of this model. 
4.2.3 Future work 
Future investigation into cellular factors determining susceptibility to prion strains would ideally 
begin by determining differences in gene expression between subclones susceptible to different 
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prion strains. As demonstrated by our recent publication (Marbiah et al., 2014) there is a gene 
signature associated with prion susceptibility which could mask differences between rare 
variant subclones. As such non-preferring subclones would serve as a baseline of gene 
expression from which to detect alterations. During isolation of subclones we observed a high 
variation in susceptibility to both prion strains across the population of subclones. Similar to the 
revertant subclones isolated by Marbiah et al (2014) some subclones displayed low to negligible 
susceptibility to both RML and 22L. These cells were largely ignored for the purposes of this 
study but in future work it may be interesting to test whether the regulatory genes identified by 
Marbiah et al also limit prion susceptibility in revertant CAD5 subclones. A key observation in 
our recent study was that prion susceptibility could be induced in prion resistant cells either by 
differentiation with retinoic acid or knockdown of any one of a subset of identified genes. 
Similarly we would be able to validate which expressed genes, if any, regulate susceptibility to 
RML or 22L by silencing identified genes in the SCA. It is also possible that increased gene 
expression would aid propagation of a distinct prion strain and as such it may be necessary to 
overexpress certain genes to induce susceptibility to a non-preferred prion strain. Structural 
differences in PrP which alter susceptibility to prion conversion have previously been 
investigated by Atarashi et al (2006).  Here substitutions in the amino acid sequence of PrP which 
altered protein conformation changed susceptibility of the resulting protein to conversion by 
22L and Chandler prion strains. Importantly the effects of these amino acid substitutions were 
strain dependent, suggesting that conformational differences in a prion strain influence the 
strain’s ability to replicate using PrPC. These conformational differences may help to explain the 
species barrier which limits zoonotic transmission of prion disease. 
In our second cohort we tested whether strain preference was stably retained over multiple 
passages. Whilst all RML-preferring and non-preferring subclones gave a similar susceptibility 
score over both assays the sole 22L-preferring subclone in this cohort lost preference and gave 
a neutral score in the repeat assay. Retesting included a higher number of technical repeats per 
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clone, and whilst these varied returned similar numbers of PrPSc-positive cells (‘spot count’) as 
in the initial screening run. We were careful to exclude clones in this run which yielded a spot 
count lower than 200 for the preferred strain as lower values would decrease differences 
between RML and 22L and so decrease the sensitivity of the susceptibility score. In the case of 
the 22L-preferring clone similar spot counts were recorded for 22L in both first and second tests, 
suggesting a renewed susceptibility to RML rather than a complete loss of susceptibility. 
Furthermore the preference for 22L was weaker across the board compared to RML. In the case 
of our 480 subclone cohort preference for RML was accompanied by almost 10-fold great 
response to RML than 22L, whilst 22L preferring subclones returned only 3- to 4-fold more spots 
for 22L than RML. Mahal et al recorded CAD5 response indexes of 19 and 10 for RML and 22L 
respectively (2007), indicating CAD5 propagate RML roughly twice as well as 22L. Although our 
subcloning runs did not record a significant difference in PrPSc-positive cells following infection 
with RML and 22L across the entire population of subclones it is possible that the CAD5 line has 
some bias towards propagation of RML. 
Given that prion strains are known to demonstrate Darwinian adaptation (Li et al., 2010) it is 
possible that passaging prion strains through differentially susceptible subclones may alter the 
strain characteristics. Indeed, it is possible that passaged strains may become ‘CAD5-adapted’, 
and may produce a homogenous novel strain regardless of infection with RML or 22L. There are 
several ways this hypothesis could be tested. Firstly, if a strain adapts to propagate in a 
permissive CAD5 subclone the strain’s characteristics may be sufficiently altered to propagate 
in all (or many) CAD5 subclones. As such it may be possible to propagate CAD5-adapted RML 
prions in a 22L-selective CAD5 subclone.  Prion strains can be separated by 2 way electrophoresis 
(Provansal et al., 2010) and it is likely that different PrP quasispecies could exhibit different 
charge and mass due to differences in conformation and glycosylation respectively. If so two-
directional gel electrophoresis could be employed to characterise RML and 22L before and after 
passage through CAD5 cells, with the aim of identifying changes in signal which could represent 
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adaptation to CAD5 cells. Furthermore we could also attempt to infect RML-preferring subclones 
with cell lysates of 22L infected 22L-preferring subclones, and vice versa. The aim of this 
experiment would be to test whether passaging in CAD5 cells sufficiently adapts a prion strain 
to allow for infection of other closely related cells.  
4.2.4 Implications for prion disease 
Although only a pilot study our work here has several implications for future study of prion 
disease. Studies into strain selection where both strains are produced from the same species, 
such as the mouse strains RML, 22L and Me7 used here, can provide insight as to how 
conformational differences in PrPSc alter its properties. Furthermore this work, and its place in 
understanding the quasispecies selection model of prion strain adaptation, could help us to 
better understand the species barrier which limits zoonotic transmission of prion disease.  
The quasispecies selection model hypothesises that prion strains contain a pool of PrPSc 
conformers of which one is dominant and gives the strain its characteristics (Collinge, 2010). 
Prion strains are known to adapt to different host species and cell lines (Li et al., 2010, Mahal et 
al., 2010) and show faster disease progression over multiple passages (Hamir et al., 2009, Baron 
et al., 2011). Theoretically these adaptions could be due to selection of different prion 
conformers which are better able to replicate in the new host environment. Our work here was 
based on the assumption that cellular factors limited the ability of prion strains to propagate in 
different cell lines, and we have demonstrated that different subclones isolated from the same 
parental cell pool display differential susceptibility to different prion strains. The conformation 
of PrPC in a host system may influence which prion strains are able to propagate. Studies into 
the synthesis of PrP suggest key folding events may occur as PrPC is post-translationally 
processed in the ER (Harris, 2003). As such if different processing occurs in different cell lines 
there may be different conformers of PrPC expressed. Different PrPC conformers may provide 
selection pressure for PrPSc quasispecies and so may alter strain characteristics over several 
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passages by selecting for a different dominant quasispecies. Indeed in 2010 Li et al were able to 
demonstrate reversible adaptation of prion strains using swainsonine. Similar to the work 
suggested above our CAD5 subclones may be able to select out CAD5-competent quasispecies 
from RML and 22L, which could be further investigated to provide evidence for pools of different 
PrPSc conformers in strains in the quasispecies model. 
A defining characteristic of prion strains is the different patterns of PrPSc deposition and brain 
lesions produced in vivo (Bruce, 1993). These lesion patterns seem to occur following trafficking 
of PrPSc from the initial site of prion infection via white matter tracts (Kordek et al., 1999) and 
suggest differential susceptibility to different prion strains across the brain. As we have shown 
here, along with other studies, prion propagation can be limited by cellular factors. As such it is 
possible that different brain areas are more susceptible to some prion strains than others, which 
may explain differences in PrPSc deposition as prions are propagated more rapidly in some types 
of neuron than others. If the toxic effect of prion disease is mediated by PrPSc then lesion 
patterns would be expected to follow brain regions where a given prion strain is more able to 
replicate. It is possible that differences in lipid composition and availability may influence the 
pattern of PrPSc deposition seen with different prion strains (Castilla and Goni, 2011). In light of 
our other data this may represent the ability of different conformers to overcome changes in 
stability in PrPC in different raft environments. In our previous work we demonstrated that the 
gene regulatory network we identified regulated susceptibility to both RML and 22L prion strains 
(Marbiah et al., 2014). We did not test our lipid targets against prion strains other than RML and 
it is possible that we would see different effects with other strains.   
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4.3 Contribution to Marbiah et al 
Throughout this thesis I make reference to earlier work of which I am a co-first author 
investigating the role of the extracellular matrix in prion replication. The abstract and citation 
for this publication (Marbiah et al, 2014) are provided in Appendix 1. I worked on this study in 
a parallel stream to my PhD project and have not included results (other than images of PrPd) in 
this thesis. In preparing the study for publication I performed multiple experiments and analysed 
SCA and confocal imaging data. Notably I assessed the effects of gene targets in CAD5 and LD9 
cells and helped characterise the PrP basement membrane density. Furthermore, I analysed 
data from my experiments and helped interpret these findings in the context of the study and 
field as a whole. 
4.4 Concluding Remarks 
I have shown here that prion replication is influenced by multiple cellular factors. Lipid rafts, 
composed of cholesterol and sphingolipids, are required for cell surface presentation of PrPC, 
stabilise the mature prion protein and may limit prion conversion. By silencing key genes 
required for cholesterol homeostasis I was able to show a shift of PrPC out of lipid raft fractions 
of cell membranes which was associated with an increase in prion replication. Our data goes 
against early suggestions that cholesterol is a co-factor for prion replication and instead suggests 
that cholesterol limits prion propagation. Further work is required to determine the molecular 
mechanism by which cholesterol reduction increases production of PrPSc. In light of work by our 
and other groups it seems likely that lipid raft association stabilises PrPC and so limits prion 
propagation. 
 I have also shown that cellular factors can lead to selective propagation of different prion 
strains. By subcloning CAD5 cells, which propagate multiple prion strains, I was able to isolate 
cells which exclusively propagated a single prion strain. In the context of existing knowledge of 
prion strains and factors which limit prion propagation our experiments could be interpreted as 
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a model for differences in cellular factors required to propagate different prion strains. To 
determine if an underlying pattern of gene expression determines which strains a cell can 
propagate an increased cohort for further study would be required.  
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Abstract 
Prions consist of aggregates of abnormal conformers of the cellular prion protein (PrPC). They 
propagate by recruiting host-encoded PrPC although the critical interacting proteins and the 
reasons for the differences in susceptibility of distinct cell lines and populations are unknown. 
We derived a lineage of cell lines with markedly differing susceptibilities, unexplained by PrPC 
expression differences, to identify such factors. Transcriptome analysis of prion-resistant 
revertants, isolated from highly susceptible cells, revealed a gene expression signature 
associated with susceptibility and modulated by differentiation. Several of these genes encode 
proteins with a role in extracellular matrix (ECM) remodelling, a compartment in which disease-
related PrP is deposited. Silencing nine of these genes significantly increased susceptibility. 
Silencing of Papss2 led to undersulphated heparan sulphate and increased PrPC deposition at 
the ECM, concomitantly with increased prion propagation. Moreover, inhibition of fibronectin 1 
binding to integrin α8 by RGD peptide inhibited metalloproteinases (MMP)-2/9 whilst increasing 
prion propagation. In summary, we have identified a gene regulatory network associated with 
prion propagation at the ECM and governed by the cellular differentiation state. 
